Sensitivity calibration of in vivo sensors used to measure analyte concentration

Information

  • Patent Grant
  • 12279866
  • Patent Number
    12,279,866
  • Date Filed
    Thursday, January 20, 2022
    3 years ago
  • Date Issued
    Tuesday, April 22, 2025
    8 months ago
Abstract
Methods, devices, systems, and computer program products are provided to improve sensitivity calibration of an in vivo analyte sensor and usability of an associated analyte monitoring system. In certain embodiments, methods are provided that improve the user experience of using an analyte monitoring system. Certain embodiments of the present disclosure include features that reduce the amount of calibration or re-calibration performed by the analyte monitoring system. More specifically methods of using a suspect calibration attempt to avoid having to recalibrate by adjusting the calibration or mitigating effects of sensor signal attenuation that caused the calibration attempt to be suspect are provided. Additional features are disclosed.
Description
BACKGROUND

The detection of the concentration level of glucose or other analytes in certain individuals may be vitally important to their health. For example, the monitoring of glucose levels is particularly important to individuals with diabetes or pre-diabetes. People with diabetes may need to monitor their glucose levels to determine when medication (e.g., insulin) is needed to reduce their glucose levels or when additional glucose is needed.


Devices have been developed for automated in vivo monitoring of analyte concentrations, such as glucose levels, in bodily fluids such as in the blood stream or in interstitial fluid. Some of these analyte level measuring devices are configured so that at least a portion of the devices are positioned below a skin surface of a user, e.g., in a blood vessel or in the subcutaneous tissue of a user. As used herein, the term analyte monitoring system is used to refer to any type of in vivo monitoring system that uses a sensor disposed with at least a portion subcutaneously to measure and store sensor data representative of analyte concentration levels automatically over time. Analyte monitoring systems include both (1) systems such as continuous glucose monitors (CGMs) which transmit sensor data continuously or at regular time intervals (e.g., once per minute) to a processor/display unit and (2) systems that transfer stored sensor data in one or more batches in response to a request from a processor/display unit (e.g., based on an activation action and/or proximity, for example, using a near field communications protocol) or at a predetermined but irregular time interval.


Determining an analyte concentration level in blood based on the analyte concentration measured using an analyte monitoring system typically involves calibrating the in vivo sensor of the analyte monitoring system using a reference measurement. For example, a finger stick blood sample may be used as a reference to determine the blood analyte concentration at a particular time and the result is paired with a corresponding measurement from the analyte monitoring system. The sensitivity of the analyte monitoring system's sensor is adjusted based on the difference and other factors. However, several factors related to the measurement from the analyte monitoring system can affect the accuracy of the calibration. Thus, what is needed are systems, methods and apparatus to improve sensitivity calibration of the in vivo sensors used to measure analyte concentration.


SUMMARY

Methods, devices, and systems are provided to improve sensitivity calibration of an in vivo analyte sensor and usability of the associated analyte monitoring system. In some embodiments, the present disclosure includes a computer-implemented method for defining a set of system checks associated with an analyte monitoring system; receiving a request to perform calibration of an in vivo sensor of an analyte monitoring system; receiving a signal representative of sensor data from the analyte monitoring system related to an analyte level of a patient measured over time; conducting calibration using a reference measurement estimated at calibration time from a first predetermined duration of reference observation paired, with a signal representative of sensor data up to the calibration time; updating calibration using the same reference measurement at a second predetermined duration of reference observation spanning the first predetermined duration and an additional period, paired with a signal representative of sensor data up to a third predetermined period relative to the calibration time; using an adjustment map that balances the risk of over and under calibration based on a priori information; deferring calibration if attenuation of a signal from the sensor is detectable at a time in which the request is received, wherein the calibration is delayed until the signal attenuation is no longer detected; performing calibration if the set of system checks pass and signal attenuation is not being detected; storing the signal from the sensor over time for a period of time spanning from before the calibration to after the calibration; determining if previously undetected signal attenuation occurred during the calibration based on the stored signal after the calibration has completed; reconstructing the signal and revising the calibration of the sensor based on the reconstructed signal if previously undetected signal attenuation occurred and if the signal can be adjusted to compensate for the previously undetected signal attenuation; invalidating the calibration and requesting a new calibration if previously undetected signal attenuation occurred and if the signal cannot be adjusted to compensate for the previously undetected signal attenuation; and displaying an analyte concentration value if previously undetected signal attenuation did not occur during calibration based on the stored signal. Related systems and computer program products are also disclosed. Numerous other aspects and embodiments are provided. Other features and aspects of the present disclosure will become more fully apparent from the following detailed description, the appended claims, and the accompanying drawings.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 depicts a flowchart illustrating an example of a first method for calibrating a sensor of an analyte monitoring system in accordance with some embodiments of the present disclosure.



FIG. 2 depicts a flowchart illustrating an example of a second method for calibrating a sensor of an analyte monitoring system in accordance with some embodiments of the present disclosure.



FIG. 3 depicts a flowchart illustrating an example of a third method for calibrating a sensor of an analyte monitoring system in accordance with some embodiments of the present disclosure.



FIG. 4 depicts a flowchart illustrating an example of a fourth method for calibrating a sensor of an analyte monitoring system in accordance with some embodiments of the present disclosure.



FIG. 5 depicts a graph of example data on a Clarke error grid in accordance with some embodiments of the present disclosure.



FIG. 6 depicts a graph of example data on a Clarke error grid in accordance with some embodiments of the present disclosure.



FIG. 7 depicts a graph summarizing the effect of stratifying the example data in FIG. 5 in accordance with some embodiments of the present disclosure.



FIG. 8 depicts a graph of an example correlation between an accuracy metric and the ratio of calibration sensitivity (Sc) to ideal sensitivity (Sn) in accordance with some embodiments of the present disclosure.



FIG. 9 depicts a graph of an example of a calibration adjustment factor derived by inverting the relative accuracy metric of FIG. 8 in accordance with some embodiments of the present disclosure.



FIG. 10 depicts a flowchart illustrating an example of a fifth method for calibrating a sensor of an analyte monitoring system in accordance with some embodiments of the present disclosure.



FIG. 11 depicts a flowchart illustrating an example of a sixth method for calibrating a sensor of an analyte monitoring system in accordance with some embodiments of the present disclosure.



FIG. 12 depicts a flowchart illustrating an example of a seventh method for calibrating a sensor of an analyte monitoring system in accordance with some embodiments of the present disclosure.





DETAILED DESCRIPTION

The present disclosure provides systems, methods, and apparatus to improve sensitivity calibration of an in vivo analyte sensor and usability of the associated analyte monitoring system. In some embodiments, the present disclosure provides methods that improve the user experience of using an analyte monitoring system. For example, in some embodiments, the present disclosure includes features that reduce the amount of calibration or re-calibration performed by the analyte monitoring system. More specifically, in some embodiments, the present disclosure provides methods of using a suspect calibration attempt to avoid having to recalibrate by adjusting the calibration or mitigating effects of sensor signal attenuation that caused the calibration attempt to be suspect. For example, sensor signal attenuating phenomena such as Early Sensitivity Attenuation (ESA) and dropouts that occur during a calibration attempt (and render the calibration attempt suspect) can be addressed in some embodiments. When ESA or a dropout occurs, the sensor still generates a signal with a lower amplitude than the true signal, but may still take on a value that is physiologically feasible. Hence, unlike signal loss, detection of either ESA or a dropout is not trivial. Unlike typical noise artifact, ESA and dropouts consistently bias the sensor output down. Standard filtering methods are not effective to compensate for neither ESA nor dropouts without incurring additional drawbacks. ESA typically occurs within the first few hours of sensor start time, and disappears thereafter. Dropouts last for much shorter periods and might occur, for example, during bedtime independent of the sensor start time.


In some embodiments, the present disclosure provides methods of analyzing sensor data received after a reference analyte concentration value is received (e.g., initiated by the user) to perform a calibration in place of a future system requested calibration. Thus, for example, if a user happens to perform a finger stick in vitro blood glucose (BG) measurement and the outcome is provided to the analyte monitoring system, the system can use the information as a reference analyte concentration value for a calibration attempt. In conventional BG systems, a reference analyte BG reading is computed based on a time series measurement in response to an analyte sample collected in a test strip. The BG system takes a predetermined duration in order to collect the time series measurement, typically in the five second range. In addition, instead of determining a sensitivity of the in vivo sensor using a real time algorithm that only considers limited sensor data in order to provide real time responsiveness regarding the success or failure of the calibration attempt, the present disclosure can take the time to consider a wider window of sensor data since the user is not waiting for an outcome indication of the calibration attempt. Therefore, not only are the number of system requested calibrations reduced, more accurate calibrations can be performed by using more data. In some embodiments, the present disclosure provides methods that improve the sensitivity calibration by using historical data to hedge against the aggregate risks of calibration errors, such as, for example, due to ESA. In some embodiments, the present disclosure uses “extra” data obtained from a test strip that remains in a BG meter after an initial reading has been made, to improve the accuracy of the initial reading and to improve the certainty of the analyte monitoring system's calibration based on the initial reading. In some embodiments, the present disclosure uses fault identification, instead of merely detecting faults, to improve the likelihood of a successful calibration attempt.


Embodiments of the present disclosure are described primarily with respect to continuous glucose monitoring devices and systems for illustrative purposes but the present disclosure can be applied to other analytes, other analyte characteristics, and other analyte measurement systems, as well as data from measurement systems that transmit sensor data from a sensor unit to another unit such as a processing or display unit in response a request from the other unit. For example, other analytes that can be monitored include, but are not limited to, acetyl choline, amylase, bilirubin, cholesterol, chorionic gonadotropin, creatine kinase (e.g., CK-MB), creatine, DNA, fructosamine, glutamine, growth hormones, hormones, ketones, lactate, peroxide, prostate-specific antigen, prothrombin, RNA, thyroid stimulating hormone, and troponin. The concentration of drugs, such as, for example, antibiotics (e.g., gentamicin, vancomycin, and the like), digitoxin, digoxin, drugs of abuse, theophylline, and warfarin, can also be monitored. In those embodiments that monitor more than one analyte, the analytes can be monitored at the same or different times. In addition, in some embodiments, the present disclosure can be applied to non-analyte sensor data. For example, non-analyte sensor data can include temperature estimation of a target physiological compartment that is made based on measuring the temperature of a nearby compartment, where the measured temperature is related to the temperature of the target compartment. The present disclosure also provides numerous additional embodiments.


Some embodiments of the present disclosure include a programmed computer system adapted to receive and store data from an analyte monitoring system. The computer system can include one or more processors for executing instructions or programs that implement the methods described herein. The computer system can include memory and persistent storage devices to store and manipulate the instructions and sensor data received from the analyte monitoring system. The computer system can also include communications facilities (e.g., wireless and/or wired) to enable transfer of the sensor data from the analyte monitoring system to the computer. The computer system can include a display and/or output devices for identifying dropouts in the sensor data to a user. The computer system can include input devices and various other components (e.g., power supply, operating system, clock, etc.) that are typically found in a conventional computer system. In some embodiments, the computer system is integral to the analyte monitoring system. For example, the computer system can be embodied as a handheld or portable receiver unit within the analyte monitoring system. In some embodiments, the analyte monitoring system may include a computer system and in some embodiments, the analyte monitoring system may include (or be in signal communication with) an analyte meter (e.g., a BG meter) configured to measure an analyte concentration in vitro.


In some embodiments, the various methods described herein for performing one or more processes, also described herein, can be embodied as computer programs (e.g., computer executable instructions and data structures). These programs can be developed using an object oriented programming language, for example, that allows the modeling of complex systems with modular objects to create abstractions that are representative of real world, physical objects and their interrelationships. However, any practicable programming language and/or techniques can be used. The software for performing the inventive processes, which can be stored in a memory or storage device of the computer system described herein, can be developed by a person of ordinary skill in the art based upon the present disclosure and can include one or more computer program products. The computer program products can be stored on a non-transitory computer readable medium such as a server memory, a computer network, the Internet, and/or a computer storage device.


Analyte monitoring systems such as Continuous Glucose Monitor (CGM) systems that use reference Blood Glucose (BG) values for calibration, pair the reference BG values with a corresponding sensor data point received in an uncalibrated sensor signal from the CGM system. There are a number of conditions which can invalidate a calibration attempt due to known hardware system, environmental, and physiological factors. A hardware system invalidating factor example includes the sensor signal transmission to the receiver, handheld, or monitoring unit has been compromised with noise or interrupted altogether. A potential environmental invalidating factor example occurs when a measured temperature is out of the operating range of the system. A physiological invalidating example occurs when the computed rate is too high, either physiologically so, such that the accuracy of certain numerical calculations can be suspect, or non-physiologically high such that the reliability of the latest sensor signal is questionable.


Temporal features of the sensor signal that do not correlate to glucose excursion can significantly affect calibration. Examples of such temporal features include Early Sensitivity Attenuation (ESA) and dropouts. Methods to detect and evaluate these features during operation of the analyte monitoring system as they occur (i.e., in real time) allows the system to determine the proper course of action. For example, if a dropout is determined to be taking place while the system is scheduled to perform a calibration, the system can delay the calibration request until the undesired artifact is deemed to have ended. On occasion, re-evaluating data from before and up to after a completed calibration can reveal that the completed calibration actually took place while an undesired temporal feature, such as a dropout, occurred. This retrospective conclusion can result in two possible scenarios. The first is that the errors in calibration due to the dropout can be corrected, so that the system revises the calibration in light of this new information. The second is that the errors in calibration due to the dropout cannot be corrected. In this case, the system may decide to invalidate the recently performed calibration either immediately or within a certain elapsed time after this determination. When the recently performed calibration is invalidated, the system will determine when to request a new calibration based on various factors including the likelihood of the persistence of undesired temporal features.


In some embodiments, the present disclosure attempts to adjust the calibration and/or mitigate the effect of temporal signal attenuations on calibration. By combining existing calibration checks and calculations with retrospective calibration and both real-time and retrospective artifact detection, such as for example, using a dropout detector, the present disclosure is able to salvage suspect calibration attempts that might otherwise require additional calibration.


Turning now to FIG. 1, an example of a method 100 according to the present disclosure is illustrated in a flowchart. As mentioned above, an analyte monitoring system can include a set of system tests or checks to determine if a calculated sensitivity value is acceptable and can be used to configure a sensor (102). For example, the system checks may include an outlier check, a comparison against sensor-code nominal sensitivity in the calibration validations check, a stability check, a calibration sensitivity check, an ESA check, and the like. When the system determines that calibration of the sensor should be performed, the system can request that the user provide a reference analyte concentration value (104). Sensor data continues to be received from the in vivo sensor while the request is pending (106). Known methods and apparatus for detecting undesired signal attenuation are used to determine if calibration should be deferred dues to signal attenuation (108). For example, U.S. Pat. No. 7,630,748 entitled “Method and System For Providing Analyte Monitoring” and incorporated herein by reference, describes a real-time dropout detector that may be used.


If undesired signal attenuation is detected, the system will delay the calibration request until the sensor has recovered and a true signal is generated. Otherwise, the system will allow calibration provided that other system checks are passed (110). The system stores the sensor data from before and after the calibration (112). Within a predetermined time after a calibration has been performed, the system retrospectively evaluates the sensor's signal quality around the moment of calibration to determine whether a previously undetected undesired signal attenuation was missed by the real-time detector(s) (114). If an undesired signal attenuation is determined to have taken place during the calibration, and if the true analyte signal can be reconstructed with good confidence, then the system revises the result of the calibration without the need of further user interaction (116). An example of such retrospective calibration is described in U.S. Pat. No. 7,618,369 entitled “Method and System For Dynamically updating Calibration Parameters For an Analyte Sensor” and incorporated herein by reference. However, if an undesired signal attenuation is determined to have taken place and the true analyte signal cannot be reconstructed with good confidence, then the system may request a new calibration (118).


In some embodiments, the system can take alternative courses of action depending on the characterization of the attenuation. In order to characterize attenuation, a detector estimates the degree of attenuation during a window of time by comparing the measured aggregate level of the signal in that window relative to a baseline level, which is computed from the same window of time using a different filter, or computed from a different window of time using a similarly structured filter. The comparison between the measured aggregate level and the baseline level is used to identify whether or not an attenuation is occurring. If adjacent time windows are deemed to be attenuated, then the time windows may be considered as a single attenuation event. For each event, a predicted time of onset and recovery may be computed. Some of the characterizations of attenuation include the direct ratio between the measured aggregate level and its baseline, a scaled ratio between the measured aggregate level and its baseline, a function such as a quadratic absolute ratio between the measured aggregate level and its baseline, the peak ratio, the duration between onset and recovery, or the area under the curve generated by the ratio and duration. One or more of these characterizations can be used to determine the various courses of action needed. If the attenuation completely invalidates the previously completed calibration, then the system can immediately expire that calibration, and the system may no longer display an analyte concentration value until a successful calibration has been performed. If the calibration is sufficiently accurate enough to provide useful analyte concentration value information for at least a short time after the calibration, the system momentarily allows the analyte concentration value display to continue, and then expires the calibration soon after. When appropriate, the system requests a new calibration in order to resume display of the analyte concentration value (120).


In some embodiments, in addition to compensating for signal attenuation, the methods of the present disclosure can assess the feasibility of a calibration attempt based on past and stored data to identify faults. Thus, instead of merely invalidating a calibration attempt because a check has failed, the present disclosure can determine useful information to avoid repeating failed calibrations in the future. The present disclosure assesses the sensor signal and reference analyte value history around the present and past calibration attempts. In some embodiments, the present disclosure determines whether a current failed calibration attempt is caused by the sensor currently producing unreliable sensor data, or whether the reference analyte concentration value is not reliable.


To illustrate the additional information provided by checking the reference value and the sensor data instead of just the sensitivity value, consider a case in which the latest calibration attempt is close enough to a prior attempt, whether or not the prior attempt was used to update sensitivity for glucose calculation. In addition to the system checks, these relatively closely spaced reference values can be compared to assess the feasibility of the reference value of the latest calibration attempt. For example, if the difference between the latest and previous reference values is too large considering the time interval between them and the assumed reference value measurement error variability, then the latest calibration attempt should be failed, even though none of the sensitivity based checks failed. In some cases, an outlier reference value could occur such that the sensitivity happens to be relatively unchanged because the error in reference value is almost cancelled by another erroneous factor in the calculation of sensitivity.


If there are several recent past reference value data available, other methods can be used. One example is to monitor the standard deviation of the predicted reference value using a regularization procedure or other data smoothing procedure. A dramatic increase in standard deviation around the latest attempt implies that the latest reference value has a relatively large uncertainty.


In addition to using reference value, one can make a better assessment of the latest calibration attempt by considering the sensor data. For example, given the best sensitivity used up to the latest attempt, the computed analyte level can be compared from the sensor data around the instances where recent past calibration attempts were made. The computed analyte level can then be tested against similar methods as described in the previous section. In addition, methods that require relatively constant sample time, such as an Auto Regressive (AR) model and Auto Regressive Moving Average (ARMA), can be used to see whether the latest sensor measurements correlated reasonably well to past data in the same manner as observed around the recent past attempts. Because of the relatively rich data content from the sensor, assessments can be made involving combinations of point wise analyte values as well as higher order signals. For example, one can track the analyte rate of change during recent past and latest calibration attempts, to determine whether including the latest calibration attempt significantly changes the rate distribution statistics of the moving average population.


The likelihood of undesired sensor transients can be checked to see if they differ dramatically between the latest attempts. For example, assuming a dropout detector is used to assess the likelihood of the sensor signal exhibiting dropouts, if the detector generates a much higher likelihood for dropouts than the previous attempts, then it is possible that at least the absolute raw sensor signal and/or the raw sensor rate of change may be far enough from the true value that a sensitivity check may not indicate an actual change in sensitivity. The combined knowledge of the relative confidence of the sensor, reference BG, and the resulting sensitivity calculation amongst relatively recent attempts can be useful in a number of ways. For example, the reference value and sensor signal comparisons are useful in qualifying the relative uncertainty of calibration attempts. By taking the combined information, one can weigh both the reference BG and sensor signal of recent past attempts, so that future calibration attempts can be compared against these values without having to resort to using equal weighting for each of the attempts. This results in a more reliable relative assessment. In some embodiments, the relative weighting can be used when generating the latest weighted sensitivity to be used in converting raw sensor signal into final glucose values as well as glucose rate of change. In other words, instead of using a fixed weighting factor that was predetermined offline, each calibration update can use all near past and latest attempts with weights that are derived from the combination of the above comparisons.


Additionally, a consistent pattern of increase or change in uncertainty over time of the sensor signal, reference value, or computed sensitivity can be used to infer that state of the system. Several possible scenarios and corresponding system actions are described below. For example, if the latest few attempts indicate that the sensor signal or sensor rate of change uncertainty increases dramatically compared to the older attempts, the system could conclude that the sensor is momentarily not ready to produce reliable measurements. The system could notify the user to delay the follow-up calibration attempt in order not to waste their effort. The delay time may depend on other checks, such as the various components of data quality check as well as the ESA detector. If the last attempt indicates that the latest reference value uncertainty is dramatically larger compared to the other past attempts, the system could conclude that the attempt must be failed because the latest reference value is likely to be an outlier. The system could notify the user to try again, possibly reminding the user to consult the user guide for the proper finger stick method.


If more than one recent reference value attempts show a relatively larger uncertainty than the older records, then the system can conclude that something systematic could be wrong with the reference value measurement process. Examples include using a new test strip vial but not correctly updating the sensor code, using alternate site testing (AST) without properly preparing the test area, and possibly using control solution instead of patient's blood as a sample source. The system could remind the user to consult the user guide for the proper finger stick method. If the persistent increase in uncertainty is too big, the system may decide to terminate operation to prevent producing results with poor accuracy.


If more than one attempt indicate that while both the reference value and the sensor signal are relatively reasonable, but the latest computed sensitivities result in a much larger uncertainty than before, then it is possible that a dramatic change has occurred. One possible cause would be a change in the effective dynamics between, for example, blood and interstitial glucose, such that the reference value and interstitial analyte value independently show no dramatic change in behavior, but their dynamic and possibly static relationship has changed. Another possible cause would be the loss of counter electrode function, in which a bias is introduced between measured interstitial analyte and blood analyte as measured by the reference value. In some embodiments, the system could elect to adjust the calibration factor with an offset factor as necessary. If several follow-up confirmatory finger sticks do not indicate that the offset-adjusted model has a good fit, then the system may decide to terminate operation.



FIG. 2 is a flow chart depicting an example method 200 of assessing the sensor signal and reference analyte value history around the present and past calibration attempts to determine whether a current failed calibration attempt is caused by the sensor producing unreliable sensor data, or whether the reference analyte concentration value is not reliable. Initially, a set of system checks associated with an analyte monitoring system is defined (202). A signal representative of sensor data is received from an analyte monitoring system related to an analyte level of a patient measured over time (204). A reference analyte concentration value is received (206). A sensitivity value is calculated based on the signal and the reference analyte concentration value (208). The system checks are performed on the sensitivity value (210). If the system checks indicate the sensitivity value is invalid, the system determines if the signal is a cause of the sensitivity value being invalid (212). If the system checks indicate the sensitivity value is invalid, the system determines if the reference analyte concentration value is a cause of the sensitivity value being invalid (214). The sensitivity value is recalculated using new sensor data after a delay if the signal was a cause of the sensitivity value being invalid (216). The sensitivity value is recalculated using a new reference analyte concentration value if the reference analyte concentration value was a cause of the sensitivity value being invalid (218). The analyte level of the patient is displayed based on the recalculated sensitivity value if the system checks indicate the sensitivity value is invalid (220).


Turning now to FIG. 3, another aspect of the present disclosure is described. In some embodiments, where a user-initiated provision of a reference analyte concentration value that happens to occur within a predetermined time period of a scheduled calibration request, is to be used for calibration, a retrospective review of the calibration may be used to improve the calibration. In other words, instead of determining a sensitivity of the in vivo sensor using a real-time algorithm that only considers limited sensor data in order to provide real-time responsiveness regarding the success or failure of the calibration attempt, the present disclosure can consider a wider window of sensor data since the user is not expecting feedback regarding a calibration attempt or, for that matter, the user is not aware of the calibration attempt at all.



FIG. 3 is a flowchart depicting an example method 300 of using retrospective analysis on calibration attempts that use a user-initiated provision of a reference analyte concentration value. For example, if a user happens to perform a finger stick in vitro blood glucose (BG) measurement and the outcome is provided to the analyte monitoring system within a predetermined time period of a scheduled calibration request, the system can use the information as a reference analyte concentration value for a calibration attempt and the calibration attempt can be retrospectively analyzed to refine the calibration.


In some embodiments, an analyte monitoring system is provided configured to request a reference analyte concentration value for use in calibrating an in vivo sensor of the analyte monitoring system (302). The request may be satisfied by a user-initiated supply of the reference analyte concentration value before the request or by a user response to the request. A signal representative of sensor data is received from the analyte monitoring system related to an analyte level of a patient measured over time (304). A first method of computing a sensitivity value for calibrating the sensor is provided wherein the sensitivity value is computed based on an amount of sensor data that is less than a predetermined amount (306). A second method of computing a sensitivity value for calibrating the sensor is provided wherein the sensitivity value is computed based on an amount of sensor data that is more than a predetermined amount (308). The sensor is calibrated using the first method when the request is satisfied by a user response to the request (310). The sensor is calibrated using the second method when the request is satisfied by a user initiated supply of the reference analyte concentration before the request (312). The analyte level of the patient is displayed based on the calibration of the sensor (314).


In some embodiments, the system attempts a full retrospective calibration on a first BG measurement and a partial and/or real-time calibration on a second BG measurement as soon as a scheduled calibration is required. The result can be a weighted average based on the relative uncertainty of the two results. In some embodiments, the weighting scheme can be dependent on the percentage of data points available to perform retrospective calibration. Once a weighted average of the two calibration values are obtained, then the system can use that value as the calibration value and the user will be relieved of having to take a measurement for the next scheduled calibration. If one of the values fails a calibration-related acceptance criteria, then the system ignores that value. If none of the values pass the system checks, then the normally scheduled calibration will occur.


In some embodiments, the system can wait for the second user-initiated BG measurement to have sufficient associated sensor data so that retrospective calibration can be performed on both user-initiated BG measurements without attempting a real-time calibration. If both calibrations pass the calibration-related acceptance criteria, then the weighted average will be used as the calibration value for the next scheduled calibration. If one calibration fails, then only the successful calibration is used. If both fail, then the normally scheduled calibration will occur.


In some embodiments, any user-initiated BG measurements prior to a next scheduled calibration can be used to update calibration parameters that are used to screen out unsuitable conditions. For example, pre-calibration screening routines may check the glucose rate of change based on an assumed sensitivity value and the analyte monitoring system's sensor signal close in time to a next scheduled calibration. Updating the sensitivity value using the user-initiated BG measurements can improve the reliability of such a pre-calibration screening routine, thereby reducing the frequency of unnecessary calibration requests that have a relatively elevated chance of failure. In some embodiments, any user-initiated BG measurement taken just prior to a BG measurement initiated by the system (e.g., a system requested measurement) for a next scheduled calibration, can be combined to obtain calibration results that are relatively insensitive to BG measurement errors, an analyte monitoring system sensor signal noise, and potential changes in system equilibrium since the last scheduled calibration. In some embodiments, the decision to use any one or combination of the above embodiments can be determined by a processor-based online logic system and/or by using rules derived offline from analysis of stored data. For example, the system can determine that a stepwise change in one or more system related parameters may be likely around the third to fourth day of the sensor wear.


In another aspect of the present disclosure, the system may take advantage of additional data available when a test strip is left in a reference BG meter beyond the time required by the meter's primary algorithm to determine a reference analyte concentration value. This extended time during which an analyte measurement system with an integrated reference BG meter would not normally monitor the output of the reference BG meter can be used to refine or improve the initial determination of the reference analyte concentration value by using the additional data. A second algorithm allows for an updated reference analyte concentration value and the uncertainty limits can be used by the analyte measurement system to further refine its calibration value.


In some embodiments, for each calibration instance, the primary algorithm produces a reference BG value to be used by the analyte measurement system's calibration algorithm. The reference BG value, together with the most recent sensor signal measurements, can be used to both evaluate the suitability of the current calibration attempt and to obtain the sensitivity (i.e., a scaling calibration factor), in order to produce an analyte measurement from the analyte measurement system. Immediately after, the second algorithm can use data from the existing primary algorithm plus any further signal from the BG meter's strip port until the strip is removed. The second algorithm then provides an updated reference BG value to the analyte measurement system's calibration algorithm, which uses the updated reference BG value to refine the sensitivity value. The update can occur several minutes after the test strip has been removed and requires no special action by the user.


In some embodiments a stream of recursive revisions of the reference BG meter glucose estimate is used to obtain a measure of the measurement's variability. The variability in the reference BG meter glucose value can then be translated into the variability of the computed sensitivity for calibration. This results in both upper and lower bounds of the estimated sensitivity. Knowing these bounds allow the relative precision of each calibration to be compared. In addition, any threshold checks could be done with these bounds taken into account. For example, if the latest rate check results in an estimate of 1.9±0.5 mg/(dL min), then a +2 mg/(dL min) maximum rate threshold may be too close for the latest calibration attempt to be allowed to succeed.


In some embodiments, the reference BG meter variability is first obtained by comparing the characteristics of a primary reference BG meter algorithm against the secondary reference BG meter algorithm operating at different extended time durations. These measurements are also compared against the known glucose concentration in the medium that the reference BG meter strip takes its measurement from. Any possible bias and offset correction as a function of the difference between the primary and secondary reference BG meter algorithm outputs as well as the duration of the extended time, can then be used to correct the reference BG meter reading used for calibration in the analyte measurement system. This online correction will be applied as soon as the secondary reference BG meter algorithm finishes. The calibration algorithm in the analyte measurement system can then be used to revise the sensitivity value based on the bias and/or offset adjusted reference BG meter reading.


In some embodiments, the correlation between the degree of certainty of a reference BG meter reading and the difference between primary and secondary reference BG meter algorithm outputs as a function of extended time duration is obtained. In an online implementation, as soon as the secondary reference BG meter algorithm finishes, the weighting of the latest sensitivity value can be adjusted by taking into account for the degree of certainty obtained offline.


Turning now to FIG. 4, an example embodiment of a method 400 is depicted as a flowchart. An analyte monitoring system is provided that is configured to receive a reference analyte concentration value for use in calibrating an in vivo sensor of the analyte monitoring system (402). The reference analyte concentration value is calculated based on a test strip inserted in a port of an in vitro analyte meter for a predetermined period of time. A signal representative of sensor data is received from the analyte monitoring system related to an analyte level of a patient measured over time (404). A first method of calculating the reference analyte concentration value is provided wherein the reference analyte concentration value is calculated based on data collected from the test strip within the predetermined period of time (406). A second method of calculating the reference analyte concentration value is provided wherein the reference analyte concentration value is calculated based on data collected from the test strip within the predetermined period of time and data collected from the test strip after the predetermined period of time (408). A sensitivity value is computed for calibrating the sensor based on the reference analyte concentration value computed using the first method (410). The sensitivity value for calibrating the sensor is re-computed based on the reference analyte concentration value computed using the second method if the test strip remains in the port of the in vitro analyte meter beyond the predetermined period (412). The sensor is calibrated using the sensitivity value (414). The analyte level of the patient is displayed based on the calibration of the sensor (416).



FIG. 5 depicts a Clarke Grid 500 of sensor data and reference BG points from a collection of experiments. The Clarke Grid shows a certain amount of data dispersion on the higher end. To relate to the ESA case, a subset of the data presented in FIG. 5 is shown in FIG. 6. In FIG. 6, only paired points where calibration took place during repressed sensitivity are displayed. As sensitivity recovers to its regular value, which is higher relative to when sensitivity is repressed, the sensor glucose values tend to display higher numbers. Composite sensitivity (Sc) is the effective sensitivity used to determine displayed glucose values at each data sample instance. As an illustrative example, the data points in Clarke Grid 600 in FIG. 6 are restricted to points whose calibration sensitivity value, Sc, is less than or equal to 7/10th of the true sensitivity. True sensitivity is computed after the fact from the median of all available sensitivities, Sm. Note that this subset of the population is the group that contributes to the high-end scatter seen in FIG. 5. As the stratification is changed from 7/10th to 8/10th, and so on, more and more of the high-end scatter seen in FIG. 5 will get included, and less and less of the ideal scatter near the 45 degree line 502 will get excluded.



FIG. 7 summarizes the effect of stratifying the data in FIG. 5 based on the ratio between the sensitivity during calibration, Sc, and the best estimate of true sensor sensitivity, Sm. The horizontal axis is the overall MARD (Mean Absolute Relative Difference) of each group, which is a metric that roughly describes the variability of the accuracy. The vertical axis is the low end MRD (Mean Relative Difference) of each group, which is a metric that roughly describes low-end bias of the accuracy. The relative size of each circle reflects the number of paired points that fall into each group, with the “All” group having the largest number of paired points. The patterns are indicative of the Percent A region of the Clarke Grid Statistics of each group, closer to the bottom being a higher Percent A value than closer to the top.


The stratification based on Sc/Sm ratio shown in FIG. 7 is presented in 10% increments from the full population (i.e. “All” group). The groups below median are those whose Sc/Sm values are less than or equal to 0.9, 0.8, 0.7 and 0.6. Similarly, the groups above median are those whose Sc/Sm values are greater than or equal to 1.1, 1.2, and 1.3. There are not enough points for the 1.4 group.


Given the equal 10% increments, it can be observed that the performance degradation in terms of marginal increase in full MARD, marginal increase in the absolute value of low end MRD, and the marginal decrease in Percent A, moves faster for the groups below the median than for the groups above the median. Practically, this means that based on the common accuracy performance metrics, the system is much more robust to a high sensitivity calibration compared to a low sensitivity calibration of the same additive percentage change. This is still the case if the comparison were to be made in the geometric percentage change sense. For example, the group where Sc/Sm is less than or equal to 0.8 should be geometrically comparable to the group where Sc/Sm is greater than or equal to 1/0.8=1.25. One would expect that this group would lie between the 1.2 and 1.3 groups in FIG. 5. While the low end MRD is not significantly different, the MARD and percent A statistics are worse for the 0.8 group.


In the general context of calibration, it can be assumed that the effective sensitivity being somewhat higher than computed is preferred over using the “as is” value or a mildly scaled down value. This observation can be combined with real-time observations of past calibrations as well as aggregate sensor sensitivity information obtained from the manufacturing lot to improve the robustness of each calibration instance. In the particular case related to ESA, where early sensitivity calculations are most likely to be underestimated, a proper scaling of this calculated value could mean improved accuracy.


Prior information regarding the sensor based on past calibrations and/or sample lot statistics is used to obtain the best nominal estimate of the sensor sensitivity. Any statistical property of this estimate, such as mean and standard deviation, can be adjusted by the risk distribution derived by information obtained from the process summarized in FIG. 10. The result is a table of correction factors on each calibration instance based on how the current calibration value compares to prior information. This table could also be a function of elapsed time since sensor start as well as elapsed time since the last calibration. For example, instead of using median sensitivity to normalize all Sc values after the fact, nominal sensor code sensitivity can be used to normalize the Sc values. A plot similar to plot 700 in FIG. 7 can then be obtained. Using this inference, a risk distribution can be obtained, where, for any given calibration, the computed sensitivity is compared to the nominal sensor code sensitivity, and a correction factor is applied to the computed sensitivity based on this comparison. In this example, the correction factor table can be obtained a priori from a database of sensor use. The correction factor table can be periodically reviewed offline to determine whether any adjustment is necessary to the algorithm. Another example would be to compute the median sensitivity based on all past calibration attempts plus the nominal sensor code sensitivity to revise the correction factor table previously described in real time during each sensor wear. The present disclosure uses information regarding the effect of over and under estimation of computed sensitivity with respect to common performance metrics such as, but not limited to low end MRD, full MRD, MARD, Clarke Grid Percent A, best fit line intercept, and root mean squared error (RMSE).



FIG. 8 is a graph 800 depicting an example correlation between an accuracy metric and the ratio of calibration sensitivity (Sc) to ideal sensitivity (Sn). FIG. 9 is a graph 900 depicting an example of a calibration adjustment factor derived by inverting the relative accuracy metric of FIG. 8. Turning to FIG. 10, a flowchart detailing an example embodiment of a method 1000 for determining an adjustment to a calibration based on the correlation of calibration error, calibrated sensitivity, and ideal sensitivity according to the present disclosure, is shown. Paired reference BG data and calibrated sensor data are collected (1002). The data is paired (1004) and grouped based on the calibration used (1006). Each “calibration” set contains applicable paired data, the calibration sensitivity, and the ideal sensitivity. Calibration sensitivity may be either immediate or composite sensitivity. Ideal sensitivity may require raw sensor data and reference values from the past. One or more accuracy metrics are selected to be used as a basis of the adjustment (1008). For example, mean relative difference (MRD) of paired values below 100 mg/dL. A correlation is found between the accuracy metric and the ratio of calibration sensitivity (Sc) to ideal sensitivity (Sn) (1010). For example, the ideal sensitivity can be the sensor-code-based sensitivity as depicted in FIG. 8. Based on the correlation, the calibration adjustment is computed, either as a lookup table (for different ranges of Sc/Sn values) or a continuous function (1012). For example, given the relative accuracy metric above, the calibration adjustment becomes a relative value. So that adjusted glucose Ga is a function of raw glucose Gr, calibration sensitivity Sc, and the calibration adjustment Kc (labeled as Glucose Correction Factor in FIG. 9).

Ga=Kc Gr/Sc, where Kc is the inverse of the Accuracy Metric.


For an additive accuracy metric such as Mean Difference, the adjustment is:

Ga=(Gr/Sc)+Kc, where Kc is the negative of the Accuracy Metric.


For subsequent calibrations, the latest function or lookup table is used to determine the necessary calibration correction (1014). The method 1000 repeats if new data becomes available (1016) or otherwise uses the latest function or lookup table (1018).



FIG. 11 is a flowchart detailing an example embodiment of a method 1100 for applying an adjustment to a calibration in real-time according to the present disclosure. Once the in vivo sensor of an analyte monitoring system has been started and an initial calibration completed, the calibration sensitivity is compared to the sensor-code-based sensitivity (1102). The sensor-code-based sensitivity is used as the ideal sensitivity. The correction function or lookup table is next used to find out the required correction given the latest calibration sensitivity, ideal sensitivity, and elapsed time since sensor started (1104). From the time of calibration to the scheduled time to the next calibration, the amount of adjustment is gradually increased from 0 to the maximum as determined by the previous process (1106). The adjustment modifies how the calibration sensitivity transforms raw signal into glucose concentration units. If the sensor is still active (1108), the method 1100 waits for the next calibration (1110) and then repeats. Otherwise, the method 1100 ends.



FIG. 12 is a flowchart detailing an example embodiment of an alternative method 1200 for applying an adjustment to a calibration in real-time according to the present disclosure. Once the in vivo sensor of an analyte monitoring system has been started and an initial calibration completed, the calibration sensitivity is compared to the sensor-code-based sensitivity (1202). In this embodiment, the median of the sensitivities from prior calibrations is used as the ideal sensitivity. The correction function or lookup table is then used to determine the required correction given the latest calibration sensitivity, ideal sensitivity, and elapsed time since sensor started (1204). From the time of calibration to the scheduled time to the next calibration, the amount of adjustment is gradually increased from 0 to the maximum as determined by the previous process (1206). The adjustment modifies how the calibration sensitivity transforms raw signal into glucose concentration units. If the sensor is still active (1208), the method 1200 waits for the next calibration (1210) and then repeats. Otherwise, the method 1200 ends.


Accordingly, in certain embodiments, a computer-implemented method includes receiving a signal representative of sensor data from an analyte sensor configured to monitor an analyte level over time, calibrating the analyte sensor if attenuation of the received signal from the analyte sensor is not detectable, deferring calibration of the analyte sensor if attenuation of the received signal from the analyte sensor is detectable when calibration is requested, wherein the calibration is deferred until the attenuation of the received signal is no longer detected, storing the signal from the analyte sensor for a period of time spanning from before the calibration to after the calibration, determining whether a previously undetected signal attenuation has occurred during the calibration based on the stored signal after the calibration has been completed, performing reconstruction of the received signal based on the stored signal from the analyte sensor for the period of time spanning from before the calibration to after the calibration, when it is determined that the previously undetected signal attenuation has occurred, to generate a reconstructed signal, updating the calibration of the analyte sensor based on the reconstructed signal, and invalidating the calibration of the analyte sensor and requesting a new calibration of the analyte sensor if performing the reconstruction of the received signal does not generate the reconstructed signal.


Certain embodiments further include displaying an analyte concentration value corresponding to the monitored analyte level if the previously undetected signal attenuation did not occur during calibration based on the stored signal, or if performing the reconstruction of the received signal generated the reconstructed signal.


Certain embodiments also include suspending displaying the analyte concentration value if the calibration of the analyte sensor is invalidated and the previously undetected signal attenuation is greater than a predefined threshold.


Certain embodiments further include displaying an analyte concentration value when the new calibration is performed and the previously undetected signal attenuation is less than a predefined threshold.


Certain embodiments further include delaying invalidating the calibration if the signal attenuation is determined to be continuing to occur.


In certain embodiments, deferring calibration if attenuation of the signal from the analyte sensor is detectable further includes detecting signal attenuation from at least one of a hardware system condition, an environmental condition, and a physiological condition.


In certain embodiments, deferring calibration if attenuation of the signal from the analyte sensor is detectable further includes detecting signal attenuation from at least one of early signal attenuation and a dropout.


A system for monitoring an analyte using an in vivo sensor in accordance with an embodiment of the present disclosure includes a processor, a memory operatively coupled to the processor, the memory storing instructions which, when executed by the processor, causes the processor to: receive a signal representative of sensor data from an analyte sensor configured to monitor an analyte level over time, calibrate the analyte sensor if attenuation of the received signal from the analyte sensor is not detectable, defer calibration of the analyte sensor if attenuation of the received signal from the analyte sensor is detectable when calibration is requested, wherein the calibration is deferred until the attenuation of the received signal is no longer detected, store the signal from the analyte sensor for a period of time spanning from before the calibration to after the calibration, determine whether a previously undetected signal attenuation has occurred during the calibration based on the stored signal after the calibration has been completed, perform reconstruction of the received signal based on the stored signal from the analyte sensor for the period of time spanning from before the calibration to after the calibration, when it is determined that the previously undetected signal attenuation has occurred, to generate a reconstructed signal, update the calibration of the analyte sensor based on the reconstructed signal, and invalidate the calibration of the analyte sensor and request a new calibration of the analyte sensor if performing the reconstruction of the received signal does not generate the reconstructed signal.


A computer program product stored on a computer-readable medium in accordance with one embodiment of the present disclosure includes instructions to: receive a signal representative of sensor data from an analyte sensor configured to monitor an analyte level over time, calibrate the analyte sensor if attenuation of the received signal from the analyte sensor is not detectable, defer calibration of the analyte sensor if attenuation of the received signal from the analyte sensor is detectable when calibration is requested, wherein the calibration is deferred until the attenuation of the received signal is no longer detected, store the signal from the analyte sensor for a period of time spanning from before the calibration to after the calibration, determine whether a previously undetected signal attenuation has occurred during the calibration based on the stored signal after the calibration has been completed, perform reconstruction of the received signal based on the stored signal from the analyte sensor for the period of time spanning from before the calibration to after the calibration, when it is determined that the previously undetected signal attenuation has occurred, to generate a reconstructed signal, update the calibration of the analyte sensor based on the reconstructed signal, and invalidate the calibration of the analyte sensor and request a new calibration of the analyte sensor if performing the reconstruction of the received signal does not generate the reconstructed signal.


Certain embodiments include a computer-implemented method comprising defining a set of system checks associated with an analyte monitoring system, receiving a signal representative of sensor data from an analyte monitoring system related to an analyte level of a patient measured over time, receiving a reference analyte concentration value, calculating a sensitivity value based on the signal and the reference analyte concentration value, performing the system checks on the sensitivity value, determining if the signal is a cause of the sensitivity value being invalid if the system checks indicate the sensitivity value is invalid, determining if the reference analyte concentration value is a cause of the sensitivity value being invalid if the system checks indicate the sensitivity value is invalid, recalculating the sensitivity value using new sensor data after a delay if the signal was a cause of the sensitivity value being invalid, recalculating the sensitivity value using a new reference analyte concentration value if the reference analyte concentration value was a cause of the sensitivity value being invalid, and displaying the analyte level of the patient based on the recalculated sensitivity value if the system checks indicate the sensitivity value is invalid.


In certain embodiments, determining if the reference analyte concentration value is a cause of the sensitivity value being invalid includes determining if a difference between the reference analyte concentration value and a prior reference analyte concentration value is larger than a predefined threshold amount wherein the prior reference analyte concentration value was received within a predefined time period of the reference analyte concentration value.


In certain embodiments, determining if the reference analyte concentration value is a cause of the sensitivity value being invalid includes determining if a difference between a standard deviation of the reference analyte concentration value and a standard deviation of a predicted reference analyte concentration is larger than a predefined threshold amount, wherein the standard deviation of the predicted reference analyte concentration is determined based on a plurality of prior reference analyte concentration values.


In certain embodiments, determining if the signal is a cause of the sensitivity value being invalid includes determining if a difference between the signal and a prior signal received during a prior calculation of a sensitivity value is larger than a predefined threshold amount wherein the prior signal was received within a predefined time period of the signal.


In certain embodiments, determining if the signal is a cause of the sensitivity value being invalid includes determining if the signal correlates with prior signals received during prior calculations of sensitivity values to within a predetermined amount.


In certain embodiments, determining if the signal is a cause of the sensitivity value being invalid includes determining if including the signal in a moving average population of prior signals received during prior calculations of sensitivity values changes a rate of change distribution of the moving average population by more than a predetermined threshold.


Certain embodiments may further comprise calculating a weighting of the sensitivity value indicative of a relative confidence rating of the accuracy of the sensitivity value, wherein the weighting is determined based on the signal and the reference analyte concentration value compared to prior signals and the reference analyte concentration values received during prior calculations of sensitivity values.


Certain embodiments include a computer-implemented method comprising providing an analyte monitoring system configured to request a reference analyte concentration value for use in calibrating an in vivo sensor of the analyte monitoring system, wherein the request may be satisfied by a user initiated supply of the reference analyte concentration value before the request or by a user response to the request, receiving a signal representative of sensor data from the analyte monitoring system related to an analyte level of a patient measured over time, providing a first method of computing a sensitivity value for calibrating the sensor wherein the sensitivity value is computed based on an amount of sensor data that is less than a predetermined amount, providing a second method of computing a sensitivity value for calibrating the sensor wherein the sensitivity value is computed based on an amount of sensor data that is more than a predetermined amount, calibrating the sensor using the first method when the request is satisfied by a user response to the request, calibrating the sensor using the second method when the request is satisfied by a user initiated supply of the reference analyte concentration before the request, and displaying the analyte level of the patient based on the calibration of the sensor.


In certain embodiments, if the user initiated supply of the reference analyte concentration occurs within a predetermined time before the request, the sensor is calibrated using the first method.


In certain embodiments, if the user supplies a reference analyte concentration before the request and a second reference analyte concentration in response to the request, a sensitivity value is computed for each analyte concentration and a weighted average of the sensitivity values is used for calibration.


In certain embodiments, if the user supplies two or more reference analyte concentrations before the request, a sensitivity value is computed for each analyte concentration and a weighted average of the sensitivity values is used for calibration.


In certain embodiments, if the user initiated supply of the reference analyte concentration occurs within a predetermined time before the request and a sensitivity value based on the second method passes an acceptance criteria, the system cancels the request and the sensor is calibrated using the second method.


Certain embodiments may further comprise defining a set of acceptance criteria for using a sensitivity value to calibrate the sensor, wherein if the user supplies two or more reference analyte concentrations, a sensitivity value is computed for each analyte concentration and the sensor is calibrated based on only sensitivity values that pass the acceptance criteria.


Certain embodiments include a computer-implemented method comprising providing an analyte monitoring system configured to receive a reference analyte concentration value for use in calibrating an in vivo sensor of the analyte monitoring system, wherein the reference analyte concentration value is calculated based on a test strip inserted in a port of an in vitro analyte meter for a predetermined period of time, receiving a signal representative of sensor data from the analyte monitoring system related to an analyte level of a patient measured over time, providing a first method of calculating the reference analyte concentration value wherein the reference analyte concentration value is calculated based on data collected from the test strip within the predetermined period of time, providing a second method of calculating the reference analyte concentration value wherein the reference analyte concentration value is calculated based on data collected from the test strip within the predetermined period of time and data collected from the test strip after the predetermined period of time, computing a sensitivity value for calibrating the sensor based on the reference analyte concentration value computed using the first method, re-computing the sensitivity value for calibrating the sensor based on the reference analyte concentration value computed using the second method if the test strip remains in the port of the in vitro analyte meter beyond the predetermined period, calibrating the sensor using the sensitivity value, and displaying the analyte level of the patient based on the calibration of the sensor.


Certain embodiments may further comprise determining a first value indicative of a variability of the reference analyte concentration value; determining a second value indicative of a variability of the sensitivity value based on the first value; and verifying validity of a subsequent calibration attempt using a subsequently computed sensitivity value based on the second value.


Certain embodiments may further comprise recursively re-computing the reference analyte concentration value based on data collected from the test strip within the predetermined period of time and data collected from the test strip after each additional passage of the predetermined period of time or fraction thereof.


In certain embodiments, re-computing the sensitivity value includes using a weighted average of the reference analyte concentration values computed using the first method and the second method.


In certain embodiments, the weighting is determined based upon historical differences between reference analyte concentration values computed using the first method and the second method.


In certain embodiments, the historical differences between reference analyte concentration values computed using the first method and the second method include reference analyte concentration values computed using the second method wherein the test strip remains in the port of the in vitro analyte meter for varying amounts of time.


Certain embodiments include a computer-implemented method comprising providing an analyte monitoring system configured to receive a reference analyte concentration value for use in calibrating an in vivo sensor of the analyte monitoring system, wherein the reference analyte concentration value is calculated based on a test strip inserted in a port of an in vitro analyte meter for a first predetermined period of time, receiving a signal representative of sensor data from the analyte monitoring system related to an analyte level of a patient measured over time, pairing the reference analyte concentration value with the sensor data in real time during the first predetermined period of time, calculating a first sensitivity value based on the reference analyte concentration value from the in vitro analyte meter during the first predetermined period of time, recursively updating the first sensitivity value for as long as the test strip remains in the port and can provide updated reference analyte concentration values, calculating a final sensitivity value after a second predetermined period of time based on sensor data up to the second predetermined time, paired with an updated reference analyte concentration value from a most recent recursive update.


In certain embodiments, the first predetermined period of time is approximately 3 seconds to approximately 10 seconds and wherein the second predetermined period of time is approximately 3 minutes to approximately 15 minutes.


Certain embodiments include a computer-implemented method comprising providing an analyte monitoring system configured to receive a reference analyte concentration value for use in calibrating an in vivo sensor of the analyte monitoring system, providing a nominal estimate of a sensitivity of the sensor based on at least one of past calibrations and sample lot statistics, adjusting one or more statistical properties of the nominal estimate based on a risk distribution, receiving a signal representative of sensor data from the analyte monitoring system related to an analyte level of a patient measured over time, computing a current sensitivity based on the reference analyte concentration value and the sensor data, determining a table of correction factors for each past calibration based on a comparison of a current sensitivity with prior sensitivity values, applying a correction factor from the table of correction factors to the computed current sensitivity to determine a corrected sensitivity, and displaying an analyte level of a patient based on the sensor being calibrated using the corrected sensitivity.


In certain embodiments, the risk distribution is derived by stratifying paired sensor data and reference analyte concentration values plotted on a Clarke Grid based on a ratio of sensor sensitivity during calibration and an estimate of true sensor sensitivity.


Certain embodiments include a computer-implemented method comprising providing an analyte monitoring system configured to receive a reference analyte concentration value for use in calibrating an in vivo sensor of the analyte monitoring system, receiving a signal representative of sensor data from the analyte monitoring system related to an analyte level of a patient measured over time, storing sensor data, calibrated sensor data, calibration information and reference analyte concentration values, pairing reference analyte concentration values with calibrated sensor data to form paired data, grouping paired data into calibration sets based on calibration sensitivity used for each paired data, computing one or more calibration error metrics for each calibration set, determining a correlation between the one or more calibration error metrics of the calibration sets and one or more measureable factors, determining a correction function that maps the determined correlation between the one or more calibration error metrics of the calibration sets and one or more measureable factors, computing a current sensitivity based on the reference analyte concentration value and the sensor data, applying a correction factor based on the correction function to the computed current sensitivity to determine a corrected sensitivity, and displaying an analyte level of a patient based on the sensor being calibrated using the corrected sensitivity.


In certain embodiments, the correction function is implemented as a look-up table.


In certain embodiments, the measureable factors include at least one of time of day of calibration, elapsed time since sensor start of calibration, and the ratio of calibration sensitivity to ideal sensitivity.


Certain embodiments may further comprise updating the correction function based on at least one of subsequently received sensor data, calibrated sensor data, calibration information and reference analyte concentration values.


Various other modifications and alterations in the structure and method of operation of the embodiments of the present disclosure will be apparent to those skilled in the art without departing from the scope and spirit of the present disclosure. Although the present disclosure has been described in connection with certain embodiments, it should be understood that the present disclosure as claimed should not be unduly limited to such embodiments. It is intended that the following claims define the scope of the present disclosure and that structures and methods within the scope of these claims and their equivalents be covered thereby.

Claims
  • 1. A method for calibrating a signal generated by a glucose sensor indicative of a glucose level, comprising: storing, by at least one processor, a first sensitivity for the glucose sensor having an in vivo portion configured to be positioned in contact with an interstitial fluid of a user and an ex vivo portion;receiving, by the at least one processor, a prior calibrated glucose level data from a sensor electronics of the glucose sensor, wherein the calibrated glucose level data is based upon a signal generated by the glucose sensor over a first time period and indicative of the glucose level of the user;receiving, by the at least one processor, a reference blood glucose measurement of the user;pairing, by the at least one processor, the reference blood glucose measurement with the calibrated glucose level data to form a paired data;determining, by the at least one processor, an adjustment for the first sensitivity of the glucose sensor, wherein the adjustment includes a scaling factor determined based on the paired data, a distribution of sensor sensitivity, and a sensor start time;calibrating, by the at least one processor, the signal generated by the glucose sensor over a second time period after the first time period to corresponding glucose level data using the stored first sensitivity and the adjustment after the glucose sensor is positioned in contact with the interstitial fluid of the user; andtransmitting, by the at least one processor, the glucose level data to a display unit.
  • 2. The method of claim 1, wherein the first sensitivity includes a median sensitivity.
  • 3. The method of claim 1, wherein the first sensitivity includes a mean sensitivity.
  • 4. The method of claim 1, wherein the calibrating includes determining a second sensitivity for the glucose sensor using the adjustment and the first sensitivity.
  • 5. The method of claim 1, further comprising storing the adjustment in a non-transitory memory of a sensor electronics for the glucose sensor.
  • 6. The method of claim 5, wherein storing the adjustment comprises storing one or more correction factors in a table.
  • 7. The method of claim 1, further comprising updating the adjustment in a non-transitory memory of the sensor electronics.
  • 8. The method of claim 1, further comprising updating the adjustment in a non-transitory memory of the sensor electronics in real time.
  • 9. The method of claim 1, wherein the first sensitivity includes a lot sensitivity of a plurality of glucose sensor of a manufacturing lot, and the plurality of glucose sensors includes the glucose sensor.
  • 10. The method of claim 9, wherein the adjustment is based on a plurality of prior sensor uses of a subset of the plurality of glucose sensors of the manufacturing lot.
  • 11. The method of claim 9, wherein the lot sensitivity includes a standard deviation.
  • 12. The method of claim 1, further comprising: receiving, by the at least one processor, a second calibrated glucose level data from a sensor electronics of the glucose sensor, wherein the second calibrated glucose level data is based upon a second signal generated by the glucose sensor over a second time period and indicative of a second glucose level of the user;receiving, by the at least one processor, a second reference blood glucose measurement of the user;pairing, by the at least one processor, the second reference blood glucose measurement with the second calibrated glucose level data to form a second paired data; anddetermining, by the at least one processor, a second adjustment for the first sensitivity of the glucose sensor, wherein the second adjustment includes a second scaling factor determined based on the second paired data, the distribution of sensor sensitivity, and the sensor start time.
  • 13. The method of claim 1, wherein the adjustment is determined based further on a correlation between a ratio of calibration sensitivity to ideal sensitivity and an accuracy metric.
  • 14. The method of claim 1, wherein the reference blood glucose measurement comprises a user-initiated reference blood glucose measurement.
  • 15. The method of claim 1, wherein the distribution of sensor sensitivity is a risk distribution.
  • 16. The method of claim 1, wherein the adjustment comprises a function.
  • 17. A device for calibrating a signal generated by a glucose sensor indicative of a glucose level, comprising: the glucose sensor having an in vivo portion configured to be positioned in contact with an interstitial fluid of a user;a non-transitory memory; andat least one processor communicatively coupled to the non-transitory memory and the glucose sensor and configured to: store a first sensitivity for the glucose sensor;receive a prior calibrated glucose level data from a sensor electronics of the glucose sensor, wherein the calibrated glucose level data is based upon a signal generated by the glucose sensor over a first time period and indicative of the glucose level of the user;receive a reference blood glucose measurement of the user;pair the reference blood glucose measurement with the calibrated glucose level data to form a paired data;determine an adjustment for the first sensitivity of the glucose sensor, wherein the adjustment includes a scaling factor determined based on the paired data, a distribution of sensor sensitivity, and a sensor start time;calibrate the signal generated by the glucose sensor over a second time period after the first time period to corresponding glucose level data using the received first sensitivity and the determined adjustment after the glucose sensor is positioned in contact with the interstitial fluid of the user; andtransmit the glucose level data to a display unit.
  • 18. The device of claim 17, wherein the first sensitivity includes a median sensitivity.
  • 19. The device of claim 17, wherein the first sensitivity includes a mean sensitivity.
  • 20. The device of claim 17, wherein the at least one processor is configured to calibrate by determining a second sensitivity for the glucose sensor using the adjustment and the first sensitivity.
  • 21. The device of claim 17, wherein the at least one processor is further configured to store the adjustment in the non-transitory memory.
  • 22. The device of claim 21, wherein the at least one processor is configured to store the adjustment by at least storing one or more correction factors in a table.
  • 23. The device of claim 17, wherein the at least one processor is further configured to update the adjustment in the non-transitory memory of the sensor electronics.
  • 24. The device of claim 17, wherein the at least one processor is further configured to update the adjustment in the non-transitory memory of the sensor electronics in real time.
  • 25. The device of claim 17, wherein the first sensitivity includes a lot sensitivity of a plurality of glucose sensor of a manufacturing lot, and the plurality of glucose sensors includes the glucose sensor.
  • 26. The device of claim 25, wherein the adjustment is based on a plurality of prior sensor uses of a subset of the plurality of glucose sensors of the manufacturing lot.
  • 27. The device of claim 25, wherein the lot sensitivity includes a standard deviation.
  • 28. The device of claim 17, wherein the at least one processor is further configured to: receive a second calibrated glucose level data from a sensor electronics of the glucose sensor, wherein the second calibrated glucose level data is based upon a second signal generated by the glucose sensor over a second time period and indicative of a second glucose level of the user;receive a second reference blood glucose measurement of the user;pair the second reference blood glucose measurement with the second calibrated glucose level data to form a second paired data; anddetermine a second adjustment for the first sensitivity of the glucose sensor, wherein the second adjustment includes a second scaling factor determined based on the second paired data, the distribution of sensor sensitivity, and the sensor start time.
  • 29. The device of claim 17, wherein the adjustment is determined based further on a correlation between a ratio of calibration sensitivity to ideal sensitivity and an accuracy metric.
  • 30. The device of claim 17, wherein the reference blood glucose measurement comprises a user-initiated reference blood glucose measurement.
  • 31. The device of claim 17, wherein the distribution of sensor sensitivity is a risk distribution.
  • 32. The device of claim 17, wherein the adjustment comprises a function.
RELATED APPLICATIONS

The present application is a continuation of U.S. patent application Ser. No. 16/256,855 filed Jan. 24, 2019, which is a continuation of U.S. patent application Ser. No. 15/789,949 filed Oct. 20, 2017, now U.S. Pat. No. 10,188,334, which is a continuation of U.S. patent application Ser. No. 15/616,916 filed Jun. 7, 2017, now U.S. Pat. No. 9,801,577, which is a continuation of U.S. patent application Ser. No. 14/066,650 filed Oct. 29, 2013, now U.S. Pat. No. 9,675,290, which claims priority to U.S. Provisional Application No. 61/720,393 filed Oct. 30, 2012, entitled “Sensitivity Calibration of In Vivo Sensors Used to Measure Analyte Concentration”, the disclosure of which is incorporated herein by reference for all purposes.

US Referenced Citations (1192)
Number Name Date Kind
683553 Carter Oct 1901 A
3581062 Aston May 1971 A
3926760 Allen et al. Dec 1975 A
3949388 Fuller Apr 1976 A
3960497 Acord et al. Jun 1976 A
3978856 Michel Sep 1976 A
4036749 Anderson Jul 1977 A
4055175 Clemens et al. Oct 1977 A
4129128 McFarlane Dec 1978 A
4245634 Albisser et al. Jan 1981 A
4327725 Cortese et al. May 1982 A
4344438 Schultz Aug 1982 A
4349728 Phillips et al. Sep 1982 A
4373527 Fischell Feb 1983 A
4392849 Petre et al. Jul 1983 A
4425920 Bourland et al. Jan 1984 A
4441968 Emmer et al. Apr 1984 A
4462048 Ross Jul 1984 A
4478976 Goertz et al. Oct 1984 A
4494950 Fischell Jan 1985 A
4509531 Ward Apr 1985 A
4527240 Kvitash Jul 1985 A
4538616 Rogoff Sep 1985 A
4545382 Higgins et al. Oct 1985 A
4619793 Lee Oct 1986 A
4650547 Gough Mar 1987 A
4671288 Gough Jun 1987 A
4703756 Gough et al. Nov 1987 A
4711245 Higgins et al. Dec 1987 A
4731051 Fischell Mar 1988 A
4731726 Allen, III Mar 1988 A
4749985 Corsberg Jun 1988 A
4750496 Reinhart et al. Jun 1988 A
4757022 Shults et al. Jul 1988 A
4759366 Callaghan Jul 1988 A
4777953 Ash et al. Oct 1988 A
4779618 Mund et al. Oct 1988 A
4854322 Ash et al. Aug 1989 A
4871351 Feingold Oct 1989 A
4890620 Gough Jan 1990 A
4925268 Iyer et al. May 1990 A
4947845 Davis Aug 1990 A
4953552 DeMarzo Sep 1990 A
4986271 Wilkins Jan 1991 A
4995402 Smith et al. Feb 1991 A
5000180 Kuypers et al. Mar 1991 A
5002054 Ash et al. Mar 1991 A
5019974 Beckers May 1991 A
5034112 Murase et al. Jul 1991 A
5050612 Matsumura Sep 1991 A
5055171 Peck Oct 1991 A
5068536 Rosenthal Nov 1991 A
5077476 Rosenthal Dec 1991 A
5082550 Rishpon et al. Jan 1992 A
5089112 Skotheim et al. Feb 1992 A
5106365 Hernandez Apr 1992 A
5113869 Nappholz et al. May 1992 A
5122925 Inpyn Jun 1992 A
5135004 Adams et al. Aug 1992 A
5145381 Volz Sep 1992 A
5148812 Verrier et al. Sep 1992 A
5165407 Wilson et al. Nov 1992 A
5199428 Obel et al. Apr 1993 A
5202261 Musho et al. Apr 1993 A
5203326 Collins Apr 1993 A
5204264 Kaminer et al. Apr 1993 A
5210778 Massart May 1993 A
5231988 Wernicke et al. Aug 1993 A
5246867 Lakowicz et al. Sep 1993 A
5262035 Gregg et al. Nov 1993 A
5262305 Heller et al. Nov 1993 A
5264103 Yoshioka et al. Nov 1993 A
5264104 Gregg et al. Nov 1993 A
5264105 Gregg et al. Nov 1993 A
5279294 Anderson et al. Jan 1994 A
5285792 Sjoquist et al. Feb 1994 A
5293877 O'Hara et al. Mar 1994 A
5299571 Mastrototaro Apr 1994 A
5313953 Yomtov et al. May 1994 A
5320715 Berg Jun 1994 A
5320725 Gregg et al. Jun 1994 A
5322063 Allen et al. Jun 1994 A
5328460 Lord et al. Jul 1994 A
5330634 Wong et al. Jul 1994 A
5340722 Wolfbeis et al. Aug 1994 A
5342789 Chick et al. Aug 1994 A
5352351 White et al. Oct 1994 A
5354449 Band et al. Oct 1994 A
5356786 Heller et al. Oct 1994 A
5360404 Novacek et al. Nov 1994 A
5365426 Siegel et al. Nov 1994 A
5372427 Padovani et al. Dec 1994 A
5376070 Purvis et al. Dec 1994 A
5379238 Stark Jan 1995 A
5384547 Lynk et al. Jan 1995 A
5390671 Lord et al. Feb 1995 A
5391250 Cheney, II et al. Feb 1995 A
5400795 Murphy et al. Mar 1995 A
5408999 Singh et al. Apr 1995 A
5411647 Johnson et al. May 1995 A
5425749 Adams Jun 1995 A
5425868 Pedersen Jun 1995 A
5431160 Wilkins Jul 1995 A
5431921 Thombre Jul 1995 A
5438983 Falcone Aug 1995 A
5462645 Albery et al. Oct 1995 A
5472317 Field et al. Dec 1995 A
5489414 Schreiber et al. Feb 1996 A
5497772 Schulman et al. Mar 1996 A
5505828 Wong et al. Apr 1996 A
5507288 Bocker et al. Apr 1996 A
5509410 Hill et al. Apr 1996 A
5514718 Lewis et al. May 1996 A
5520191 Karlsson et al. May 1996 A
5531878 Vadgama et al. Jul 1996 A
5532686 Urbas et al. Jul 1996 A
5543326 Heller et al. Aug 1996 A
5552997 Massart Sep 1996 A
5568400 Stark et al. Oct 1996 A
5568806 Cheney, II et al. Oct 1996 A
5569186 Lord et al. Oct 1996 A
5582184 Erickson et al. Dec 1996 A
5586553 Halili et al. Dec 1996 A
5593852 Heller et al. Jan 1997 A
5601435 Quy Feb 1997 A
5609575 Larson et al. Mar 1997 A
5628310 Rao et al. May 1997 A
5628890 Carter et al. May 1997 A
5634468 Platt et al. Jun 1997 A
5640954 Pfeiffer et al. Jun 1997 A
5653239 Pompei et al. Aug 1997 A
5660163 Schulman et al. Aug 1997 A
5665222 Heller et al. Sep 1997 A
5695623 Michel et al. Dec 1997 A
5707502 McCaffrey et al. Jan 1998 A
5711001 Bussan et al. Jan 1998 A
5711861 Ward et al. Jan 1998 A
5720295 Greenhut et al. Feb 1998 A
5724030 Urbas et al. Mar 1998 A
5733259 Valcke et al. Mar 1998 A
5735285 Albert et al. Apr 1998 A
5741211 Renirie et al. Apr 1998 A
5749907 Mann May 1998 A
5772586 Heinonen et al. Jun 1998 A
5785660 van Lake et al. Jul 1998 A
5786439 Van Antwerp et al. Jul 1998 A
5791344 Schulman et al. Aug 1998 A
5792065 Xue et al. Aug 1998 A
5804047 Karube et al. Sep 1998 A
5820551 Hill et al. Oct 1998 A
5822715 Worthington et al. Oct 1998 A
5863400 Drummond et al. Jan 1999 A
5891047 Lander et al. Apr 1999 A
5891049 Cyrus et al. Apr 1999 A
5899855 Brown May 1999 A
5914026 Blubaugh, Jr. et al. Jun 1999 A
5918603 Brown Jul 1999 A
5925021 Castellano et al. Jul 1999 A
5935224 Svancarek et al. Aug 1999 A
5942979 Luppino Aug 1999 A
5951485 Cyrus et al. Sep 1999 A
5957854 Besson et al. Sep 1999 A
5960797 Kramer et al. Oct 1999 A
5961451 Reber et al. Oct 1999 A
5964993 Blubaugh, Jr. et al. Oct 1999 A
5965380 Heller et al. Oct 1999 A
5971922 Arita et al. Oct 1999 A
5995860 Sun et al. Nov 1999 A
6001067 Shults et al. Dec 1999 A
6016443 Ekwall et al. Jan 2000 A
6021350 Mathson Feb 2000 A
6024699 Surwit et al. Feb 2000 A
6038469 Karlsson et al. Mar 2000 A
6049727 Crothall Apr 2000 A
6071391 Gotoh et al. Jun 2000 A
6073031 Helstab et al. Jun 2000 A
6083710 Heller et al. Jul 2000 A
6088608 Schulman et al. Jul 2000 A
6091976 Pfeiffer et al. Jul 2000 A
6091987 Thompson Jul 2000 A
6093172 Funderburk et al. Jul 2000 A
6103033 Say et al. Aug 2000 A
6108577 Benser Aug 2000 A
6112116 Fischell Aug 2000 A
6115622 Minoz Sep 2000 A
6115628 Stadler et al. Sep 2000 A
6117290 Say et al. Sep 2000 A
6119028 Schulman et al. Sep 2000 A
6120676 Heller et al. Sep 2000 A
6121009 Heller et al. Sep 2000 A
6121611 Lindsay et al. Sep 2000 A
6122351 Schlueter, Jr. et al. Sep 2000 A
6128526 Stadler et al. Oct 2000 A
6130623 MacLellan et al. Oct 2000 A
6134461 Say et al. Oct 2000 A
6143164 Heller et al. Nov 2000 A
6144837 Quy Nov 2000 A
6144871 Saito et al. Nov 2000 A
6159147 Lichter et al. Dec 2000 A
6161095 Brown Dec 2000 A
6162611 Heller et al. Dec 2000 A
6168957 Matzinger et al. Jan 2001 B1
6175752 Say et al. Jan 2001 B1
6200265 Walsh et al. Mar 2001 B1
6212416 Ward et al. Apr 2001 B1
6212417 Ikeda et al. Apr 2001 B1
6219574 Cormier et al. Apr 2001 B1
6223283 Chaiken et al. Apr 2001 B1
6233471 Berner et al. May 2001 B1
6233486 Ekwall et al. May 2001 B1
6237394 Harris et al. May 2001 B1
6248067 Causey, III et al. Jun 2001 B1
6249705 Snell Jun 2001 B1
6254586 Mann et al. Jul 2001 B1
6256538 Ekwall Jul 2001 B1
6264606 Ekwall et al. Jul 2001 B1
6270455 Brown Aug 2001 B1
6272379 Fischell et al. Aug 2001 B1
6275717 Gross et al. Aug 2001 B1
6283761 Joao Sep 2001 B1
6284478 Heller et al. Sep 2001 B1
6291200 LeJeune et al. Sep 2001 B1
6293925 Safabash et al. Sep 2001 B1
6294997 Paratore et al. Sep 2001 B1
6295506 Heinonen et al. Sep 2001 B1
6299757 Feldman et al. Oct 2001 B1
6306104 Cunningham et al. Oct 2001 B1
6309884 Cooper et al. Oct 2001 B1
6329161 Heller et al. Dec 2001 B1
6338790 Feldman et al. Jan 2002 B1
6348640 Navot et al. Feb 2002 B1
6359444 Grimes Mar 2002 B1
6360888 McIvor et al. Mar 2002 B1
6361503 Starobin et al. Mar 2002 B1
6366794 Moussy et al. Apr 2002 B1
6368141 VanAntwerp et al. Apr 2002 B1
6377828 Chaiken et al. Apr 2002 B1
6377852 Bornzin et al. Apr 2002 B1
6377894 Deweese et al. Apr 2002 B1
6379301 Worthington et al. Apr 2002 B1
6381493 Stadler et al. Apr 2002 B1
6387048 Schulman et al. May 2002 B1
6400974 Lesho Jun 2002 B1
6405066 Essenpreis et al. Jun 2002 B1
6413393 Van Antwerp et al. Jul 2002 B1
6416471 Kumar et al. Jul 2002 B1
6418346 Nelson et al. Jul 2002 B1
6424847 Mastrototaro et al. Jul 2002 B1
6427088 Bowman, IV et al. Jul 2002 B1
6440068 Brown et al. Aug 2002 B1
6461496 Feldman et al. Oct 2002 B1
6471689 Joseph et al. Oct 2002 B1
6475372 Ohara et al. Nov 2002 B1
6475750 Han et al. Nov 2002 B1
6478736 Mault Nov 2002 B1
6484046 Say et al. Nov 2002 B1
6496729 Thompson Dec 2002 B2
6497655 Linberg et al. Dec 2002 B1
6501983 Natarajan et al. Dec 2002 B1
6503381 Gotoh et al. Jan 2003 B1
6514460 Fendrock Feb 2003 B1
6514718 Heller et al. Feb 2003 B2
6520326 McIvor et al. Feb 2003 B2
6522903 Berman et al. Feb 2003 B1
6540891 Stewart et al. Apr 2003 B1
6544212 Galley et al. Apr 2003 B2
6549796 Sohrab Apr 2003 B2
6551494 Heller et al. Apr 2003 B1
6558320 Causey, III et al. May 2003 B1
6558321 Burd et al. May 2003 B1
6558351 Steil et al. May 2003 B1
6560471 Heller et al. May 2003 B1
6561975 Pool et al. May 2003 B1
6561978 Conn et al. May 2003 B1
6562001 Lebel et al. May 2003 B2
6564105 Starkweather et al. May 2003 B2
6565509 Say et al. May 2003 B1
6571128 Lebel et al. May 2003 B2
6572542 Houben et al. Jun 2003 B1
6574490 Abbink et al. Jun 2003 B2
6574510 Von Arx et al. Jun 2003 B2
6576101 Heller et al. Jun 2003 B1
6577899 Lebel et al. Jun 2003 B2
6579231 Phipps Jun 2003 B1
6579690 Bonnecaze et al. Jun 2003 B1
6585644 Lebel et al. Jul 2003 B2
6587704 Fine et al. Jul 2003 B1
6591125 Buse et al. Jul 2003 B1
6592745 Feldman et al. Jul 2003 B1
6595919 Berner et al. Jul 2003 B2
6600997 Deweese et al. Jul 2003 B2
6605200 Mao et al. Aug 2003 B1
6605201 Mao et al. Aug 2003 B1
6607509 Bobroff et al. Aug 2003 B2
6610012 Mault Aug 2003 B2
6616819 Liamos et al. Sep 2003 B1
6618934 Feldman et al. Sep 2003 B1
6622045 Snell et al. Sep 2003 B2
6633772 Ford et al. Oct 2003 B2
6635014 Starkweather et al. Oct 2003 B2
6635167 Batman et al. Oct 2003 B1
6641533 Causey, III et al. Nov 2003 B2
6648821 Lebel et al. Nov 2003 B2
6650471 Doi Nov 2003 B2
6654625 Say et al. Nov 2003 B1
6656114 Poulson et al. Dec 2003 B1
6658396 Tang et al. Dec 2003 B1
6659948 Lebel et al. Dec 2003 B2
6668196 Villegas et al. Dec 2003 B1
6675030 Ciuczak et al. Jan 2004 B2
6676816 Mao et al. Jan 2004 B2
6687546 Lebel et al. Feb 2004 B2
6689056 Kilcoyne et al. Feb 2004 B1
6694191 Starkweather et al. Feb 2004 B2
6695860 Ward et al. Feb 2004 B1
6698269 Baber et al. Mar 2004 B2
6702857 Brauker et al. Mar 2004 B2
6721582 Trepagnier et al. Apr 2004 B2
6730200 Stewart et al. May 2004 B1
6731976 Penn et al. May 2004 B2
6731985 Poore et al. May 2004 B2
6733446 Lebel et al. May 2004 B2
6735183 O'Toole et al. May 2004 B2
6736957 Forrow et al. May 2004 B1
6740075 Lebel et al. May 2004 B2
6741877 Shults et al. May 2004 B1
6746582 Heller et al. Jun 2004 B2
6749740 Liamos et al. Jun 2004 B2
6758810 Lebel et al. Jul 2004 B2
6764581 Forrow et al. Jul 2004 B1
6770030 Schaupp et al. Aug 2004 B1
6773671 Lewis et al. Aug 2004 B1
6790178 Mault et al. Sep 2004 B1
6804558 Haller et al. Oct 2004 B2
6809653 Mann et al. Oct 2004 B1
6810290 Lebel et al. Oct 2004 B2
6811533 Lebel et al. Nov 2004 B2
6811534 Bowman, IV et al. Nov 2004 B2
6813519 Lebel et al. Nov 2004 B2
6850790 Berner et al. Feb 2005 B2
6850859 Schuh Feb 2005 B1
6862465 Shults et al. Mar 2005 B2
6865407 Kimball et al. Mar 2005 B2
6873268 Lebel et al. Mar 2005 B2
6878112 Linberg et al. Apr 2005 B2
6881551 Heller et al. Apr 2005 B2
6882940 Potts et al. Apr 2005 B2
6892085 McIvor et al. May 2005 B2
6893545 Gotoh et al. May 2005 B2
6895263 Shin et al. May 2005 B2
6895265 Silver May 2005 B2
6912413 Rantala et al. Jun 2005 B2
6923763 Kovatchev et al. Aug 2005 B1
6923764 Aceti et al. Aug 2005 B2
6931327 Goode, Jr. et al. Aug 2005 B2
6932892 Chen et al. Aug 2005 B2
6932894 Mao et al. Aug 2005 B2
6936006 Sabra Aug 2005 B2
6940403 Kail, IV Sep 2005 B2
6941163 Ford et al. Sep 2005 B2
6942518 Liamos et al. Sep 2005 B2
6950708 Bowman, IV et al. Sep 2005 B2
6954662 Freger et al. Oct 2005 B2
6958705 Lebel et al. Oct 2005 B2
6968294 Gutta et al. Nov 2005 B2
6971274 Olin Dec 2005 B2
6974437 Lebel et al. Dec 2005 B2
6990366 Say et al. Jan 2006 B2
6997907 Safabash et al. Feb 2006 B2
6998247 Monfre et al. Feb 2006 B2
7003336 Holker et al. Feb 2006 B2
7003340 Say et al. Feb 2006 B2
7003341 Say et al. Feb 2006 B2
7009511 Mazar et al. Mar 2006 B2
7010345 Hill et al. Mar 2006 B2
7011630 Desai et al. Mar 2006 B2
7016713 Gardner et al. Mar 2006 B2
7016720 Kroll Mar 2006 B2
7020508 Stivoric et al. Mar 2006 B2
7022072 Fox et al. Apr 2006 B2
7022219 Mansouri et al. Apr 2006 B2
7024236 Ford et al. Apr 2006 B2
7024245 Lebel et al. Apr 2006 B2
7025425 Kovatchev et al. Apr 2006 B2
7029443 Kroll Apr 2006 B2
7029444 Shin et al. Apr 2006 B2
7041068 Freeman et al. May 2006 B2
7041468 Drucker et al. May 2006 B2
7043287 Khalil et al. May 2006 B1
7043305 KenKnight et al. May 2006 B2
7052472 Miller et al. May 2006 B1
7052483 Wojcik May 2006 B2
7056302 Douglas Jun 2006 B2
7058453 Nelson et al. Jun 2006 B2
7060031 Webb et al. Jun 2006 B2
7074307 Simpson et al. Jul 2006 B2
7076300 Kroll et al. Jul 2006 B1
7081195 Simpson et al. Jul 2006 B2
7082334 Boute et al. Jul 2006 B2
7092891 Maus et al. Aug 2006 B2
7096064 Deno et al. Aug 2006 B2
7098803 Mann et al. Aug 2006 B2
7103412 Kroll Sep 2006 B1
7108778 Simpson et al. Sep 2006 B2
7110803 Shults et al. Sep 2006 B2
7113821 Sun et al. Sep 2006 B1
7118667 Lee Oct 2006 B2
7123950 Mannheimer Oct 2006 B2
7125382 Zhou et al. Oct 2006 B2
7134999 Brauker et al. Nov 2006 B2
7136689 Shults et al. Nov 2006 B2
7142911 Boileau et al. Nov 2006 B2
7153265 Vachon Dec 2006 B2
7167818 Brown Jan 2007 B2
7171274 Starkweather et al. Jan 2007 B2
7183102 Monfre et al. Feb 2007 B2
7190988 Say et al. Mar 2007 B2
7192450 Brauker et al. Mar 2007 B2
7198606 Boecker et al. Apr 2007 B2
7203549 Schommer et al. Apr 2007 B2
7220387 Flaherty et al. May 2007 B2
7225535 Feldman et al. Jun 2007 B2
7226978 Tapsak et al. Jun 2007 B2
7228182 Healy et al. Jun 2007 B2
7237712 DeRocco et al. Jul 2007 B2
7258673 Racchini et al. Aug 2007 B2
7267665 Steil et al. Sep 2007 B2
7272436 Gill et al. Sep 2007 B2
7276029 Goode, Jr. et al. Oct 2007 B2
7278983 Ireland et al. Oct 2007 B2
7295867 Berner et al. Nov 2007 B2
7297114 Gill et al. Nov 2007 B2
7299082 Feldman et al. Nov 2007 B2
7310544 Brister et al. Dec 2007 B2
7317938 Lorenz et al. Jan 2008 B2
7318816 Bobroff et al. Jan 2008 B2
7324850 Persen et al. Jan 2008 B2
7335294 Heller et al. Feb 2008 B2
7347819 Lebel et al. Mar 2008 B2
7354420 Steil et al. Apr 2008 B2
7364592 Carr-Brendel et al. Apr 2008 B2
7366556 Brister et al. Apr 2008 B2
7379765 Petisce et al. May 2008 B2
7384397 Zhang et al. Jun 2008 B2
7387010 Sunshine et al. Jun 2008 B2
7399277 Saidara et al. Jul 2008 B2
7402153 Steil et al. Jul 2008 B2
7419573 Gundel Sep 2008 B2
7424318 Brister et al. Sep 2008 B2
7460898 Brister et al. Dec 2008 B2
7467003 Brister et al. Dec 2008 B2
7468125 Kraft et al. Dec 2008 B2
7471972 Rhodes et al. Dec 2008 B2
7474992 Ariyur Jan 2009 B2
7491303 Sakata et al. Feb 2009 B2
7492254 Bandy et al. Feb 2009 B2
7494465 Brister et al. Feb 2009 B2
7497827 Brister et al. Mar 2009 B2
7499002 Blasko et al. Mar 2009 B2
7502644 Gill et al. Mar 2009 B2
7519408 Rasdal et al. Apr 2009 B2
7519478 Bartkowiak et al. Apr 2009 B2
7523004 Bartkowiak et al. Apr 2009 B2
7524287 Bharmi Apr 2009 B2
7547281 Hayes et al. Jun 2009 B2
7565197 Haubrich et al. Jul 2009 B2
7569030 Lebel et al. Aug 2009 B2
7574266 Dudding et al. Aug 2009 B2
7577469 Aronowitz et al. Aug 2009 B1
7583990 Goode, Jr. et al. Sep 2009 B2
7591801 Brauker et al. Sep 2009 B2
7599726 Goode, Jr. et al. Oct 2009 B2
7602310 Mann et al. Oct 2009 B2
7604178 Stewart Oct 2009 B2
7613491 Boock et al. Nov 2009 B2
7615007 Shults et al. Nov 2009 B2
7618369 Hayter et al. Nov 2009 B2
7620438 He Nov 2009 B2
7630748 Budiman Dec 2009 B2
7632228 Brauker et al. Dec 2009 B2
7635594 Holmes et al. Dec 2009 B2
7637868 Saint et al. Dec 2009 B2
7640048 Dobbles et al. Dec 2009 B2
7659823 Killian et al. Feb 2010 B1
7668596 Von Arx et al. Feb 2010 B2
7699775 Desai et al. Apr 2010 B2
7699964 Feldman et al. Apr 2010 B2
7711493 Bartkowiak et al. May 2010 B2
7736310 Taub et al. Jun 2010 B2
7741734 Joannopoulos et al. Jun 2010 B2
7751864 Buck, Jr. Jul 2010 B2
7766829 Sloan et al. Aug 2010 B2
7771352 Shults et al. Aug 2010 B2
7774145 Bruaker et al. Aug 2010 B2
7778680 Goode, Jr. et al. Aug 2010 B2
7779332 Karr et al. Aug 2010 B2
7782192 Jeckelmann et al. Aug 2010 B2
7783333 Brister et al. Aug 2010 B2
7791467 Mazar et al. Sep 2010 B2
7792562 Shults et al. Sep 2010 B2
7826981 Goode, Jr. et al. Nov 2010 B2
7831310 Lebel et al. Nov 2010 B2
7842174 Zhou et al. Nov 2010 B2
7857760 Brister et al. Dec 2010 B2
7860574 Von Arx et al. Dec 2010 B2
7866026 Wang et al. Jan 2011 B1
7882611 Shah et al. Feb 2011 B2
7885697 Brister et al. Feb 2011 B2
7889069 Fifolt et al. Feb 2011 B2
7899511 Shults et al. Mar 2011 B2
7905833 Brister et al. Mar 2011 B2
7912674 Killoren Clark et al. Mar 2011 B2
7914450 Goode, Jr. et al. Mar 2011 B2
7916013 Stevenson Mar 2011 B2
7920906 Goode et al. Apr 2011 B2
7938797 Estes May 2011 B2
7946984 Brister et al. May 2011 B2
7955258 Goscha et al. Jun 2011 B2
7970448 Shults et al. Jun 2011 B2
7974672 Shults et al. Jul 2011 B2
7999674 Kamen Aug 2011 B2
8060173 Goode, Jr. et al. Nov 2011 B2
8072310 Everhart Dec 2011 B1
8090445 Ginggen Jan 2012 B2
8093991 Stevenson et al. Jan 2012 B2
8094009 Allen et al. Jan 2012 B2
8098159 Batra et al. Jan 2012 B2
8098160 Howarth et al. Jan 2012 B2
8098161 Lavedas Jan 2012 B2
8098201 Choi et al. Jan 2012 B2
8098208 Ficker et al. Jan 2012 B2
8102021 Degani Jan 2012 B2
8102154 Bishop et al. Jan 2012 B2
8102263 Yeo et al. Jan 2012 B2
8102789 Rosar et al. Jan 2012 B2
8103241 Young et al. Jan 2012 B2
8103325 Swedlow et al. Jan 2012 B2
8111042 Bennett Feb 2012 B2
8115488 McDowell Feb 2012 B2
8116681 Baarman Feb 2012 B2
8116683 Baarman Feb 2012 B2
8116837 Huang Feb 2012 B2
8117481 Anselmi et al. Feb 2012 B2
8120493 Burr Feb 2012 B2
8124452 Sheats Feb 2012 B2
8130093 Mazar et al. Mar 2012 B2
8131351 Kalgren et al. Mar 2012 B2
8131365 Zhang et al. Mar 2012 B2
8131565 Dicks et al. Mar 2012 B2
8132037 Fehr et al. Mar 2012 B2
8135352 Langsweirdt et al. Mar 2012 B2
8136735 Arai et al. Mar 2012 B2
8138925 Downie et al. Mar 2012 B2
8140160 Pless et al. Mar 2012 B2
8140168 Olson et al. Mar 2012 B2
8140299 Siess Mar 2012 B2
8140312 Hayter et al. Mar 2012 B2
8150321 Winter et al. Apr 2012 B2
8150516 Levine et al. Apr 2012 B2
8160900 Taub et al. Apr 2012 B2
8170803 Kamath et al. May 2012 B2
8179266 Hermle May 2012 B2
8211016 Budiman Jul 2012 B2
8216137 Budiman Jul 2012 B2
8216138 McGarraugh et al. Jul 2012 B1
8224415 Budiman et al. Jul 2012 B2
8239166 Hayter et al. Aug 2012 B2
8255026 Al-Ali Aug 2012 B1
8282549 Brauker et al. Oct 2012 B2
8376945 Hayter et al. Feb 2013 B2
8396670 St-Pierre Mar 2013 B2
8444560 Hayter et al. May 2013 B2
8457703 Al-Ali Jun 2013 B2
8484005 Hayter et al. Jul 2013 B2
8532935 Budiman Sep 2013 B2
8543354 Luo et al. Sep 2013 B2
8571808 Hayter Oct 2013 B2
8608923 Zhou et al. Dec 2013 B2
8612163 Hayter et al. Dec 2013 B2
8657746 Roy Feb 2014 B2
8682615 Hayter et al. Mar 2014 B2
9060719 Hayter et al. Jun 2015 B2
9113828 Budiman Aug 2015 B2
9241631 Valdes et al. Jan 2016 B2
9398872 Hayter et al. Jul 2016 B2
9408566 Hayter et al. Aug 2016 B2
9483608 Hayter et al. Nov 2016 B2
9504471 Lee et al. Nov 2016 B2
9558325 Hayter et al. Jan 2017 B2
9801577 Budiman et al. Oct 2017 B2
9808574 Yodfat et al. Nov 2017 B2
10820842 Harper Nov 2020 B2
10827954 Hoss et al. Nov 2020 B2
10874338 Stafford Dec 2020 B2
10881341 Curry et al. Jan 2021 B1
10945647 Mazza Mar 2021 B2
10945649 Lee et al. Mar 2021 B2
10952653 Harper Mar 2021 B2
10959654 Curry et al. Mar 2021 B2
10966644 Stafford Apr 2021 B2
10973443 Funderburk et al. Apr 2021 B2
11000213 Kamath et al. May 2021 B2
11000216 Curry et al. May 2021 B2
11013440 Lee et al. May 2021 B2
11020031 Simpson et al. Jun 2021 B1
11064917 Simpson et al. Jul 2021 B2
11141084 Funderburk et al. Oct 2021 B2
20010041831 Starkweather et al. Nov 2001 A1
20020010390 Guice et al. Jan 2002 A1
20020016534 Trepagnier et al. Feb 2002 A1
20020019022 Dunn et al. Feb 2002 A1
20020042090 Heller et al. Apr 2002 A1
20020043651 Darrow et al. Apr 2002 A1
20020065454 Lebel et al. May 2002 A1
20020068860 Clark Jun 2002 A1
20020072784 Sheppard et al. Jun 2002 A1
20020103499 Perez et al. Aug 2002 A1
20020106709 Potts et al. Aug 2002 A1
20020120186 Keimel Aug 2002 A1
20020128594 Das et al. Sep 2002 A1
20020143266 Bock Oct 2002 A1
20020143372 Snell et al. Oct 2002 A1
20020156355 Gough Oct 2002 A1
20020161288 Shin et al. Oct 2002 A1
20020169635 Shillingburg Nov 2002 A1
20020177764 Sohrab Nov 2002 A1
20020193679 Malave et al. Dec 2002 A1
20030003524 Taniike et al. Jan 2003 A1
20030004403 Drinan et al. Jan 2003 A1
20030023317 Brauker et al. Jan 2003 A1
20030023461 Quintanilla et al. Jan 2003 A1
20030032867 Crothall et al. Feb 2003 A1
20030032874 Rhodes et al. Feb 2003 A1
20030042137 Mao et al. Mar 2003 A1
20030050546 Desai et al. Mar 2003 A1
20030054428 Monfre et al. Mar 2003 A1
20030065308 Lebel et al. Apr 2003 A1
20030076082 Morgan et al. Apr 2003 A1
20030100821 Heller et al. May 2003 A1
20030125612 Fox et al. Jul 2003 A1
20030130616 Steil et al. Jul 2003 A1
20030134347 Heller et al. Jul 2003 A1
20030168338 Gao et al. Sep 2003 A1
20030176933 Lebel et al. Sep 2003 A1
20030187338 Say et al. Oct 2003 A1
20030191377 Robinson et al. Oct 2003 A1
20030199744 Buse et al. Oct 2003 A1
20030199790 Boecker et al. Oct 2003 A1
20030208113 Mault et al. Nov 2003 A1
20030212317 Kovatchev et al. Nov 2003 A1
20030212379 Bylund et al. Nov 2003 A1
20030216630 Jersey-Willuhn et al. Nov 2003 A1
20030217966 Tapsak et al. Nov 2003 A1
20030235817 Bartkowiak et al. Dec 2003 A1
20040010186 Kimball et al. Jan 2004 A1
20040010207 Flaherty et al. Jan 2004 A1
20040011671 Shults et al. Jan 2004 A1
20040018486 Dunn et al. Jan 2004 A1
20040022438 Hibbard Feb 2004 A1
20040024553 Monfre et al. Feb 2004 A1
20040039298 Abreu Feb 2004 A1
20040040840 Mao et al. Mar 2004 A1
20040045879 Shults et al. Mar 2004 A1
20040054263 Moerman et al. Mar 2004 A1
20040064068 DeNuzzio et al. Apr 2004 A1
20040077962 Kroll Apr 2004 A1
20040078065 Kroll Apr 2004 A1
20040093167 Braig et al. May 2004 A1
20040099529 Mao et al. May 2004 A1
20040106858 Say et al. Jun 2004 A1
20040122353 Shahmirian et al. Jun 2004 A1
20040127777 Ruchti et al. Jul 2004 A1
20040133164 Funderburk et al. Jul 2004 A1
20040135684 Steinthal et al. Jul 2004 A1
20040138588 Saikley et al. Jul 2004 A1
20040138716 Kon et al. Jul 2004 A1
20040142403 Hetzel et al. Jul 2004 A1
20040146909 Duong et al. Jul 2004 A1
20040152622 Keith et al. Aug 2004 A1
20040162678 Hetzel et al. Aug 2004 A1
20040167801 Say et al. Aug 2004 A1
20040171921 Say et al. Sep 2004 A1
20040172307 Gruber Sep 2004 A1
20040176672 Silver et al. Sep 2004 A1
20040186362 Brauker et al. Sep 2004 A1
20040186365 Jin et al. Sep 2004 A1
20040193025 Steil et al. Sep 2004 A1
20040193090 Lebel et al. Sep 2004 A1
20040197846 Hockersmith et al. Oct 2004 A1
20040199056 Husemann et al. Oct 2004 A1
20040199059 Brauker et al. Oct 2004 A1
20040204687 Mogensen et al. Oct 2004 A1
20040208780 Faries, Jr. et al. Oct 2004 A1
20040225338 Lebel et al. Nov 2004 A1
20040236200 Say et al. Nov 2004 A1
20040244151 Sakata et al. Dec 2004 A1
20040249253 Racchini et al. Dec 2004 A1
20040249420 Olson et al. Dec 2004 A1
20040254433 Bandis et al. Dec 2004 A1
20040254434 Goodnow et al. Dec 2004 A1
20040260478 Schwamm Dec 2004 A1
20040263354 Mann et al. Dec 2004 A1
20040267300 Mace Dec 2004 A1
20050003470 Nelson et al. Jan 2005 A1
20050004439 Shin et al. Jan 2005 A1
20050004494 Perez et al. Jan 2005 A1
20050010087 Banet et al. Jan 2005 A1
20050010269 Lebel et al. Jan 2005 A1
20050016276 Guan et al. Jan 2005 A1
20050017864 Tsoukalis Jan 2005 A1
20050027177 Shin et al. Feb 2005 A1
20050027180 Goode et al. Feb 2005 A1
20050027181 Goode et al. Feb 2005 A1
20050027462 Goode et al. Feb 2005 A1
20050027463 Goode et al. Feb 2005 A1
20050031689 Shults et al. Feb 2005 A1
20050038332 Saidara et al. Feb 2005 A1
20050043598 Goode, Jr. et al. Feb 2005 A1
20050049179 Davidson et al. Mar 2005 A1
20050049473 Desai et al. Mar 2005 A1
20050059871 Gough et al. Mar 2005 A1
20050069892 Iyengar et al. Mar 2005 A1
20050070774 Addison et al. Mar 2005 A1
20050090607 Tapsak et al. Apr 2005 A1
20050096511 Fox et al. May 2005 A1
20050096512 Fox et al. May 2005 A1
20050112169 Brauker et al. May 2005 A1
20050113653 Fox et al. May 2005 A1
20050114068 Chey et al. May 2005 A1
20050115832 Simpson et al. Jun 2005 A1
20050121322 Say et al. Jun 2005 A1
20050131346 Douglas Jun 2005 A1
20050143635 Kamath et al. Jun 2005 A1
20050143636 Zhang et al. Jun 2005 A1
20050151976 Toma Jul 2005 A1
20050154271 Rasdal et al. Jul 2005 A1
20050176136 Burd et al. Aug 2005 A1
20050177398 Watanabe et al. Aug 2005 A1
20050182306 Sloan Aug 2005 A1
20050187720 Goode, Jr. et al. Aug 2005 A1
20050192494 Ginsberg Sep 2005 A1
20050192557 Brauker et al. Sep 2005 A1
20050195930 Spital et al. Sep 2005 A1
20050196821 Monfre et al. Sep 2005 A1
20050199494 Say et al. Sep 2005 A1
20050203360 Brauker et al. Sep 2005 A1
20050214892 Kovatchev et al. Sep 2005 A1
20050215871 Feldman et al. Sep 2005 A1
20050239154 Feldman et al. Oct 2005 A1
20050239156 Drucker et al. Oct 2005 A1
20050241957 Mao et al. Nov 2005 A1
20050245795 Goode, Jr. et al. Nov 2005 A1
20050245799 Brauker et al. Nov 2005 A1
20050245839 Stivoric et al. Nov 2005 A1
20050245904 Estes et al. Nov 2005 A1
20050277164 Drucker et al. Dec 2005 A1
20050277912 John Dec 2005 A1
20050287620 Heller et al. Dec 2005 A1
20050288725 Hettrick et al. Dec 2005 A1
20060001538 Kraft et al. Jan 2006 A1
20060004270 Bedard et al. Jan 2006 A1
20060010098 Goodnow et al. Jan 2006 A1
20060015020 Neale et al. Jan 2006 A1
20060015024 Brister et al. Jan 2006 A1
20060016700 Brister et al. Jan 2006 A1
20060017923 Ruchti et al. Jan 2006 A1
20060019327 Brister et al. Jan 2006 A1
20060020186 Brister et al. Jan 2006 A1
20060020187 Brister et al. Jan 2006 A1
20060020188 Kamath et al. Jan 2006 A1
20060020189 Brister et al. Jan 2006 A1
20060020190 Kamath et al. Jan 2006 A1
20060020191 Brister et al. Jan 2006 A1
20060020192 Brister et al. Jan 2006 A1
20060025662 Buse et al. Feb 2006 A1
20060025663 Talbot et al. Feb 2006 A1
20060029177 Cranford, Jr. et al. Feb 2006 A1
20060031094 Cohen et al. Feb 2006 A1
20060036139 Brister et al. Feb 2006 A1
20060036140 Brister et al. Feb 2006 A1
20060036141 Kamath et al. Feb 2006 A1
20060036142 Brister et al. Feb 2006 A1
20060036143 Brister et al. Feb 2006 A1
20060036144 Brister et al. Feb 2006 A1
20060036145 Brister et al. Feb 2006 A1
20060058588 Zdeblick Mar 2006 A1
20060091006 Wang et al. May 2006 A1
20060094944 Chuang May 2006 A1
20060094945 Barman et al. May 2006 A1
20060142651 Brister et al. Jun 2006 A1
20060155180 Brister et al. Jul 2006 A1
20060166629 Reggiardo Jul 2006 A1
20060167365 Bharmi Jul 2006 A1
20060167517 Gill et al. Jul 2006 A1
20060167518 Gill et al. Jul 2006 A1
20060167519 Gill et al. Jul 2006 A1
20060173260 Gaoni et al. Aug 2006 A1
20060173406 Hayes et al. Aug 2006 A1
20060173444 Choy et al. Aug 2006 A1
20060183984 Dobbles et al. Aug 2006 A1
20060183985 Brister et al. Aug 2006 A1
20060189851 Tvig et al. Aug 2006 A1
20060189863 Peyser et al. Aug 2006 A1
20060193375 Lee Aug 2006 A1
20060222566 Brauker et al. Oct 2006 A1
20060224109 Steil et al. Oct 2006 A1
20060226985 Goodnow et al. Oct 2006 A1
20060229512 Petisce et al. Oct 2006 A1
20060247508 Fennell Nov 2006 A1
20060247685 Bharmi Nov 2006 A1
20060247710 Goetz et al. Nov 2006 A1
20060247985 Liamos et al. Nov 2006 A1
20060258929 Goode, Jr. et al. Nov 2006 A1
20060258959 Sode Nov 2006 A1
20060264785 Dring et al. Nov 2006 A1
20060272652 Stocker et al. Dec 2006 A1
20060281985 Ward et al. Dec 2006 A1
20060287691 Drew Dec 2006 A1
20060293576 Van Antwerp et al. Dec 2006 A1
20070016381 Kamath et al. Jan 2007 A1
20070027381 Stafford Feb 2007 A1
20070032706 Kamath et al. Feb 2007 A1
20070033074 Nitzan et al. Feb 2007 A1
20070038044 Dobbles et al. Feb 2007 A1
20070055799 Koehler et al. Mar 2007 A1
20070056858 Chen et al. Mar 2007 A1
20070060803 Liljeryd et al. Mar 2007 A1
20070060814 Stafford Mar 2007 A1
20070066873 Kamath et al. Mar 2007 A1
20070068807 Feldman et al. Mar 2007 A1
20070071681 Gadkar et al. Mar 2007 A1
20070073129 Shah et al. Mar 2007 A1
20070078320 Stafford Apr 2007 A1
20070078321 Mazza et al. Apr 2007 A1
20070078322 Stafford Apr 2007 A1
20070078323 Reggiardo et al. Apr 2007 A1
20070095661 Wang et al. May 2007 A1
20070106135 Sloan et al. May 2007 A1
20070108048 Wang et al. May 2007 A1
20070118030 Bruce et al. May 2007 A1
20070118405 Campbell et al. May 2007 A1
20070124002 Estes et al. May 2007 A1
20070129621 Kellogg et al. Jun 2007 A1
20070149875 Ouyang et al. Jun 2007 A1
20070156033 Causey, III et al. Jul 2007 A1
20070163880 Woo et al. Jul 2007 A1
20070168224 Letzt et al. Jul 2007 A1
20070173706 Neinast et al. Jul 2007 A1
20070173709 Petisce et al. Jul 2007 A1
20070173710 Petisce et al. Jul 2007 A1
20070173761 Kanderian et al. Jul 2007 A1
20070179349 Hoyme et al. Aug 2007 A1
20070179352 Randlov et al. Aug 2007 A1
20070179434 Weinert et al. Aug 2007 A1
20070191701 Feldman et al. Aug 2007 A1
20070199818 Petyt et al. Aug 2007 A1
20070202562 Curry et al. Aug 2007 A1
20070203407 Hoss et al. Aug 2007 A1
20070203966 Brauker et al. Aug 2007 A1
20070213657 Jennewine et al. Sep 2007 A1
20070227911 Wang et al. Oct 2007 A1
20070232877 He Oct 2007 A1
20070232878 Kovatchev et al. Oct 2007 A1
20070232880 Siddiqui et al. Oct 2007 A1
20070233013 Schoenberg et al. Oct 2007 A1
20070235331 Simpson et al. Oct 2007 A1
20070244383 Talbot et al. Oct 2007 A1
20070249922 Peyser et al. Oct 2007 A1
20070253021 Mehta et al. Nov 2007 A1
20070255321 Gerber et al. Nov 2007 A1
20070255531 Drew Nov 2007 A1
20070258395 Jollota et al. Nov 2007 A1
20070270672 Hayter Nov 2007 A1
20070285238 Batra Dec 2007 A1
20070299617 Willis Dec 2007 A1
20080004515 Jennewine et al. Jan 2008 A1
20080004601 Jennewine et al. Jan 2008 A1
20080009692 Stafford Jan 2008 A1
20080012701 Kass et al. Jan 2008 A1
20080017522 Heller et al. Jan 2008 A1
20080018433 Pitt-Pladdy Jan 2008 A1
20080021666 Goode, Jr. et al. Jan 2008 A1
20080021972 Huelskamp et al. Jan 2008 A1
20080029391 Mao et al. Feb 2008 A1
20080030369 Mann et al. Feb 2008 A1
20080033254 Kamath et al. Feb 2008 A1
20080039702 Hayter et al. Feb 2008 A1
20080045824 Tapsak et al. Feb 2008 A1
20080058625 McGarraugh et al. Mar 2008 A1
20080064937 McGarraugh et al. Mar 2008 A1
20080064943 Talbot et al. Mar 2008 A1
20080066305 Wang et al. Mar 2008 A1
20080071156 Brister et al. Mar 2008 A1
20080071157 McGarraugh et al. Mar 2008 A1
20080071158 McGarraugh et al. Mar 2008 A1
20080071328 Haubrich et al. Mar 2008 A1
20080081977 Hayter et al. Apr 2008 A1
20080083617 Simpson et al. Apr 2008 A1
20080086042 Brister et al. Apr 2008 A1
20080086044 Brister et al. Apr 2008 A1
20080086273 Shults et al. Apr 2008 A1
20080087544 Zhou et al. Apr 2008 A1
20080097289 Steil et al. Apr 2008 A1
20080102441 Chen et al. May 2008 A1
20080108942 Brister et al. May 2008 A1
20080119703 Brister et al. May 2008 A1
20080119705 Patel et al. May 2008 A1
20080119708 Budiman May 2008 A1
20080139910 Mastrototaro et al. Jun 2008 A1
20080148873 Wang Jun 2008 A1
20080154513 Kovatchev et al. Jun 2008 A1
20080161666 Feldman et al. Jul 2008 A1
20080167543 Say et al. Jul 2008 A1
20080167572 Stivoric et al. Jul 2008 A1
20080172205 Breton et al. Jul 2008 A1
20080177149 Weinert et al. Jul 2008 A1
20080177165 Blomquist et al. Jul 2008 A1
20080183060 Steil et al. Jul 2008 A1
20080183061 Goode et al. Jul 2008 A1
20080183399 Goode et al. Jul 2008 A1
20080188731 Brister et al. Aug 2008 A1
20080188796 Steil et al. Aug 2008 A1
20080189051 Goode et al. Aug 2008 A1
20080194934 Ray et al. Aug 2008 A1
20080194935 Brister et al. Aug 2008 A1
20080194936 Goode et al. Aug 2008 A1
20080194937 Goode et al. Aug 2008 A1
20080194938 Brister et al. Aug 2008 A1
20080195232 Carr-Brendel et al. Aug 2008 A1
20080195967 Goode et al. Aug 2008 A1
20080197024 Simpson et al. Aug 2008 A1
20080200788 Brister et al. Aug 2008 A1
20080200789 Brister et al. Aug 2008 A1
20080200791 Simpson et al. Aug 2008 A1
20080201325 Doniger et al. Aug 2008 A1
20080208025 Shults et al. Aug 2008 A1
20080208113 Damiano et al. Aug 2008 A1
20080214910 Buck Sep 2008 A1
20080214915 Brister et al. Sep 2008 A1
20080214918 Brister et al. Sep 2008 A1
20080228051 Shults et al. Sep 2008 A1
20080228054 Shults et al. Sep 2008 A1
20080234943 Ray et al. Sep 2008 A1
20080235469 Drew Sep 2008 A1
20080242961 Brister et al. Oct 2008 A1
20080242963 Essenpreis et al. Oct 2008 A1
20080255434 Hayter et al. Oct 2008 A1
20080255437 Hayter Oct 2008 A1
20080255438 Saidara et al. Oct 2008 A1
20080255808 Hayter Oct 2008 A1
20080256048 Hayter Oct 2008 A1
20080262469 Brister et al. Oct 2008 A1
20080267823 Wang et al. Oct 2008 A1
20080275313 Brister et al. Nov 2008 A1
20080278332 Fennel et al. Nov 2008 A1
20080287761 Hayter Nov 2008 A1
20080287762 Hayter Nov 2008 A1
20080287763 Hayter Nov 2008 A1
20080287764 Rasdal et al. Nov 2008 A1
20080287765 Rasdal et al. Nov 2008 A1
20080287766 Rasdal et al. Nov 2008 A1
20080288180 Hayter Nov 2008 A1
20080288204 Hayter et al. Nov 2008 A1
20080296155 Shults et al. Dec 2008 A1
20080300572 Rankers et al. Dec 2008 A1
20080306368 Goode et al. Dec 2008 A1
20080306434 Dobbles et al. Dec 2008 A1
20080306435 Kamath et al. Dec 2008 A1
20080306444 Brister et al. Dec 2008 A1
20080312518 Jina et al. Dec 2008 A1
20080312841 Hayter Dec 2008 A1
20080312842 Hayter Dec 2008 A1
20080312844 Hayter et al. Dec 2008 A1
20080312845 Hayter et al. Dec 2008 A1
20080314395 Kovatchev et al. Dec 2008 A1
20080319279 Ramsay et al. Dec 2008 A1
20080319295 Bernstein et al. Dec 2008 A1
20080319296 Bernstein et al. Dec 2008 A1
20090005665 Hayter et al. Jan 2009 A1
20090005666 Shin et al. Jan 2009 A1
20090006034 Hayter et al. Jan 2009 A1
20090006061 Thukral et al. Jan 2009 A1
20090012376 Agus Jan 2009 A1
20090012379 Goode et al. Jan 2009 A1
20090018424 Kamath et al. Jan 2009 A1
20090018425 Ouyang et al. Jan 2009 A1
20090030293 Cooper et al. Jan 2009 A1
20090030294 Petisce et al. Jan 2009 A1
20090033482 Hayter et al. Feb 2009 A1
20090036747 Hayter et al. Feb 2009 A1
20090036758 Brauker et al. Feb 2009 A1
20090036760 Hayter Feb 2009 A1
20090036763 Brauker et al. Feb 2009 A1
20090043181 Brauker et al. Feb 2009 A1
20090043182 Brauker et al. Feb 2009 A1
20090043525 Brauker et al. Feb 2009 A1
20090043541 Brauker et al. Feb 2009 A1
20090043542 Brauker et al. Feb 2009 A1
20090045055 Rhodes et al. Feb 2009 A1
20090048503 Dalal et al. Feb 2009 A1
20090054745 Jennewine et al. Feb 2009 A1
20090054748 Feldman et al. Feb 2009 A1
20090054749 He Feb 2009 A1
20090054753 Robinson et al. Feb 2009 A1
20090055149 Hayter et al. Feb 2009 A1
20090062633 Brauker et al. Mar 2009 A1
20090062635 Brauker et al. Mar 2009 A1
20090062767 VanAntwerp et al. Mar 2009 A1
20090063402 Hayter Mar 2009 A1
20090069649 Budiman Mar 2009 A1
20090076356 Simpson et al. Mar 2009 A1
20090076360 Brister et al. Mar 2009 A1
20090076361 Kamath et al. Mar 2009 A1
20090082693 Stafford Mar 2009 A1
20090085768 Patel et al. Apr 2009 A1
20090099436 Brister et al. Apr 2009 A1
20090102678 Mazza et al. Apr 2009 A1
20090105554 Stahmann et al. Apr 2009 A1
20090105570 Sloan et al. Apr 2009 A1
20090105636 Hayter et al. Apr 2009 A1
20090112478 Mueller, Jr. et al. Apr 2009 A1
20090112626 Talbot et al. Apr 2009 A1
20090118589 Ueshima et al. May 2009 A1
20090124877 Goode, Jr. et al. May 2009 A1
20090124878 Goode et al. May 2009 A1
20090124879 Brister et al. May 2009 A1
20090124964 Leach et al. May 2009 A1
20090131768 Simpson et al. May 2009 A1
20090131769 Leach et al. May 2009 A1
20090131776 Simpson et al. May 2009 A1
20090131777 Simpson et al. May 2009 A1
20090137886 Shariati et al. May 2009 A1
20090137887 Shariati et al. May 2009 A1
20090143659 Li et al. Jun 2009 A1
20090143660 Brister et al. Jun 2009 A1
20090143725 Peyser et al. Jun 2009 A1
20090149728 Van Antwerp et al. Jun 2009 A1
20090150186 Cohen et al. Jun 2009 A1
20090156919 Brister et al. Jun 2009 A1
20090156924 Shariati et al. Jun 2009 A1
20090163789 Say et al. Jun 2009 A1
20090163790 Brister et al. Jun 2009 A1
20090163791 Brister et al. Jun 2009 A1
20090163855 Shin et al. Jun 2009 A1
20090164190 Hayter Jun 2009 A1
20090164239 Hayter et al. Jun 2009 A1
20090164251 Hayter Jun 2009 A1
20090178459 Li et al. Jul 2009 A1
20090182217 Li et al. Jul 2009 A1
20090182517 Gandhi et al. Jul 2009 A1
20090189738 Hermle Jul 2009 A1
20090192366 Mensinger et al. Jul 2009 A1
20090192380 Shariati et al. Jul 2009 A1
20090192722 Shariati et al. Jul 2009 A1
20090192724 Brauker et al. Jul 2009 A1
20090192745 Kamath et al. Jul 2009 A1
20090192751 Kamath et al. Jul 2009 A1
20090198118 Hayter et al. Aug 2009 A1
20090203981 Brauker et al. Aug 2009 A1
20090204341 Brauker et al. Aug 2009 A1
20090216103 Brister et al. Aug 2009 A1
20090234200 Husheer Sep 2009 A1
20090240120 Mensinger et al. Sep 2009 A1
20090240128 Mensinger et al. Sep 2009 A1
20090240193 Mensinger et al. Sep 2009 A1
20090242399 Kamath et al. Oct 2009 A1
20090242425 Kamath et al. Oct 2009 A1
20090247855 Boock et al. Oct 2009 A1
20090247856 Boock et al. Oct 2009 A1
20090247857 Harper et al. Oct 2009 A1
20090257911 Thomas et al. Oct 2009 A1
20090267765 Greene et al. Oct 2009 A1
20090281407 Budiman Nov 2009 A1
20090287073 Boock et al. Nov 2009 A1
20090287074 Shults et al. Nov 2009 A1
20090289796 Blumberg Nov 2009 A1
20090294277 Thomas et al. Dec 2009 A1
20090299155 Yang et al. Dec 2009 A1
20090299156 Simpson et al. Dec 2009 A1
20090299162 Brauker et al. Dec 2009 A1
20090299276 Brauker et al. Dec 2009 A1
20100010324 Brauker et al. Jan 2010 A1
20100010331 Brauker et al. Jan 2010 A1
20100010332 Brauker et al. Jan 2010 A1
20100057040 Hayter Mar 2010 A1
20100057041 Hayter Mar 2010 A1
20100057042 Hayter Mar 2010 A1
20100057044 Hayter Mar 2010 A1
20100057057 Hayter et al. Mar 2010 A1
20100063372 Potts et al. Mar 2010 A1
20100064764 Hayter et al. Mar 2010 A1
20100081906 Hayter et al. Apr 2010 A1
20100081909 Budiman et al. Apr 2010 A1
20100081953 Syeda-Mahmood et al. Apr 2010 A1
20100121167 McGarraugh et al. May 2010 A1
20100141656 Krieftewirth Jun 2010 A1
20100145377 Lai et al. Jun 2010 A1
20100152561 Goodnow et al. Jun 2010 A1
20100160759 Celentano et al. Jun 2010 A1
20100160761 Say et al. Jun 2010 A1
20100168538 Keenan et al. Jul 2010 A1
20100168546 Kamath et al. Jul 2010 A1
20100174266 Estes Jul 2010 A1
20100190435 Cook et al. Jul 2010 A1
20100191085 Budiman Jul 2010 A1
20100191472 Doniger et al. Jul 2010 A1
20100198034 Thomas et al. Aug 2010 A1
20100198142 Sloan et al. Aug 2010 A1
20100204557 Kiaie et al. Aug 2010 A1
20100213057 Feldman et al. Aug 2010 A1
20100230285 Hoss Sep 2010 A1
20100234710 Budiman et al. Sep 2010 A1
20100261987 Kamath et al. Oct 2010 A1
20100265073 Harper et al. Oct 2010 A1
20100274515 Hoss et al. Oct 2010 A1
20100277342 Sicurello et al. Nov 2010 A1
20100280441 Willinska et al. Nov 2010 A1
20100280782 Harper et al. Nov 2010 A1
20100313105 Nekoomaram et al. Dec 2010 A1
20100317952 Budiman et al. Dec 2010 A1
20100324392 Yee et al. Dec 2010 A1
20100326842 Mazza et al. Dec 2010 A1
20110004276 Blair et al. Jan 2011 A1
20110021889 Hoss et al. Jan 2011 A1
20110024043 Boock et al. Feb 2011 A1
20110024307 Simpson et al. Feb 2011 A1
20110027127 Simpson et al. Feb 2011 A1
20110027453 Boock et al. Feb 2011 A1
20110027458 Boock et al. Feb 2011 A1
20110028815 Simpson et al. Feb 2011 A1
20110028816 Simpson et al. Feb 2011 A1
20110029247 Kalathil Feb 2011 A1
20110036714 Zhou et al. Feb 2011 A1
20110040163 Telson et al. Feb 2011 A1
20110060530 Fennell Mar 2011 A1
20110077490 Simpson et al. Mar 2011 A1
20110077494 Doniger et al. Mar 2011 A1
20110081726 Berman et al. Apr 2011 A1
20110082484 Saravia et al. Apr 2011 A1
20110105873 Feldman et al. May 2011 A1
20110106126 Love et al. May 2011 A1
20110112696 Yodfat et al. May 2011 A1
20110148905 Simmons et al. Jun 2011 A1
20110152637 Kateraas et al. Jun 2011 A1
20110184268 Taub Jul 2011 A1
20110190603 Stafford Aug 2011 A1
20110191044 Stafford Aug 2011 A1
20110193704 Harper et al. Aug 2011 A1
20110208027 Wagner et al. Aug 2011 A1
20110208155 Palerm et al. Aug 2011 A1
20110213225 Bernstein et al. Sep 2011 A1
20110224523 Budiman Sep 2011 A1
20110257495 Hoss et al. Oct 2011 A1
20110257895 Brauker et al. Oct 2011 A1
20110263958 Brauker et al. Oct 2011 A1
20110288574 Curry et al. Nov 2011 A1
20110319729 Donnay et al. Dec 2011 A1
20110320130 Valdes et al. Dec 2011 A1
20110320167 Budiman Dec 2011 A1
20120010642 Lee et al. Jan 2012 A1
20120078071 Bohm et al. Mar 2012 A1
20120108931 Taub May 2012 A1
20120108934 Valdes et al. May 2012 A1
20120165626 Irina et al. Jun 2012 A1
20120165640 Galley et al. Jun 2012 A1
20120173200 Breton et al. Jul 2012 A1
20120209099 Ljuhs et al. Aug 2012 A1
20120215462 Goode et al. Aug 2012 A1
20120245447 Karan et al. Sep 2012 A1
20120277565 Budiman Nov 2012 A1
20120283542 McGarraugh Nov 2012 A1
20120318670 Karinka et al. Dec 2012 A1
20130035575 Mayou et al. Feb 2013 A1
20130137953 Harper et al. May 2013 A1
20130184547 Taub et al. Jul 2013 A1
20130231541 Hayter et al. Sep 2013 A1
20130324823 Koski et al. Dec 2013 A1
20140005499 Catt et al. Jan 2014 A1
20140046160 Terashima et al. Feb 2014 A1
20140088392 Bernstein et al. Mar 2014 A1
20140121480 Budiman et al. May 2014 A1
20140121488 Budiman May 2014 A1
20140221966 Buckingham et al. Aug 2014 A1
20150005601 Hoss et al. Jan 2015 A1
20150216456 Budiman Aug 2015 A1
20150241407 Ou et al. Aug 2015 A1
20150366510 Budiman Dec 2015 A1
20160022221 Ou et al. Jan 2016 A1
20160302701 Bhavaraju et al. Oct 2016 A1
20170112531 Schoonmaker et al. Apr 2017 A1
20190274598 Scott et al. Sep 2019 A1
20220142518 Budiman et al. May 2022 A1
Foreign Referenced Citations (50)
Number Date Country
0098592 Jan 1984 EP
0127958 Dec 1984 EP
0320109 Jun 1989 EP
0353328 Feb 1990 EP
0390390 Oct 1990 EP
0396788 Nov 1990 EP
0472411 Feb 1992 EP
0286118 Jan 1995 EP
0867146 Sep 1998 EP
1048264 Nov 2000 EP
1391728 Feb 2004 EP
1419731 May 2004 EP
0939602 Sep 2004 EP
1850909 Apr 2010 EP
1677668 Jul 2010 EP
1 413 879 Jan 2012 EP
3575796 Dec 2019 EP
WO-1996025089 Aug 1996 WO
WO-1996035370 Nov 1996 WO
WO-1997015227 May 1997 WO
WO-1998035053 Aug 1998 WO
WO-1999056613 Nov 1999 WO
WO-0049941 Aug 2000 WO
WO-2000049940 Aug 2000 WO
WO-2000059370 Oct 2000 WO
WO-2000074753 Dec 2000 WO
WO-2001052935 Jul 2001 WO
WO-2001054753 Aug 2001 WO
WO-2002016905 Feb 2002 WO
WO 02058537 Aug 2002 WO
WO-03012422 Feb 2003 WO
WO-03032411 Apr 2003 WO
WO-2003076893 Sep 2003 WO
WO-2003082091 Oct 2003 WO
WO-03094714 Nov 2003 WO
WO-2004060455 Jul 2004 WO
WO-2005010756 Feb 2005 WO
WO-2005011489 Feb 2005 WO
WO-2005065542 Jul 2005 WO
WO-2005070287 Aug 2005 WO
WO-2006024671 Mar 2006 WO
WO 2006026741 Mar 2006 WO
WO-2006081336 Aug 2006 WO
WO-2007097754 Aug 2007 WO
WO-2008021913 Feb 2008 WO
WO-2008086541 Jul 2008 WO
WO-2010022387 Feb 2010 WO
WO-2010099507 Sep 2010 WO
WO-2011011643 Jan 2011 WO
WO-2012142502 Oct 2012 WO
Non-Patent Literature Citations (257)
Entry
U.S. Appl. No. 61/227,967, filed Jul. 23, 2009, Hoss, et al.
Bard, A. J., et al., Electrochemical Methods, Fundamentals and Applications, John Wiley & Sons, pp. 174-175.
Chen, T., et al., “In Situ Assembled Mass-Transport Controlling Micromembranes and Their Application in Implanted Amperometric Glucose Sensors”, Analytical Chemistry, vol. 72, No. 16, 2000, pp. 3757-3763.
Chen, T., et al., In vivo Glucose Monitoring with Miniature “Wired” Glucose Oxidase Electrodes, Analytical Sciences, vol. 17, 2001, pp. i297-i300.
Chen, X., et al., “Glucose microbiosensor based on alumina sol gel matrix. electropolymerized composite membrane”, Biosensors and Bioelectronics, 2002, 9 pages.
Chung, T. D., “In vitro Evaluation of the Continuous Monitoring Glucose Sensors with Perfluorinated Tetrafluoroethylene Coatings”, Bull. Korean Chem. Soc., vol. 24, No. 4, 2003, pp. 514-516.
Cunningham, D. D., et al., “In Vivo Glucose Sensing”, Chemical Analysis: A Series of Monographs on Analytical Chemistry and Its Applications, vol. 174, John Wiley & Sons, Inc., 2010, 466 pages.
Freestyle Navigator, Continuous Glucose Monitoring System, User's Guide, 2008, Abbott, 195 pages.
Guardian® REAL-Time, Continuous Glucose Monitoring System, User Guide, Medtronic MiniMed, Inc., 2006, 181 pages.
Guardian® RT, Continuous Glucose Monitoring System, REF MMT-7900, User Guide, Medtronic MiniMed, 2005, 128 pages.
Heller, A., “Implanted Electrochemical Glucose Sensors for the Management of Diabetes”, Annual Review of Biomedical Engineering, vol. 1, 1999, pp. 153-175.
Heller, A., et al., “Electrochemical Glucose Sensors and Their Applications in Diabetes Management”, Chemical Reviews, 2008, pp. 2482-2505.
Jimenez, C., et al., “Glucose sensor based on an amperometric microelectrode with a photopolymerizable enzyme membrane”, Sensors and Actuators B 26-27, 1995, pp. 421-424.
Klonoff, D. C., et al., “Diabetes Technology & Therapeutics”, vol. 5, No. 4, 2003, 14 pages.
Moatti-Sirat, D., et al., Evaluating in vitro and in vivo the interference of ascorbate and acetaminophen on glucose detection by a needle-type glucose sensor, Biosensors & Bioelectronics, 7, 1992, pp. 345-349.
Nishida, K., et al., “Development of a ferrocene-mediated needle-type glucose sensor covered with newly designed biocompatible membrane, 2-methacryloyloxyethyl phosphorylcholine-co-n-butyl methacrylate”, Medical Progress through Technology, vol. 21, 1995, pp. 91-103.
Rhodes, R. K., et al., “Prediction of Pocket-Portable and Implantable Glucose Enzyme Electrode Performance from Combined Species Permeability and Digital Simulation Analysis”, Analytical Chemistry. vol. 66, No. 9, 1994. pp. 1520-1529.
Summary of Safety and Effectiveness Data, FreeStyle Navigator® Continuous Glucose Monitoring System, Abbott Diabetes Care, 2008, 27 pages.
Tierney, M. J., et al., “Effect of Acetaminophen on the Accuracy of Glucose Measurements Obtained with the GlucoWatch Biographer”, Diabetes Technology & Therapeutics, vol. 2, No. 2, 2000, pp. 199-208.
Yang, S., et al., “Glucose Biosensors Based on Oxygen Electrode with Sandwich-Type Membranes”, Annals of Biomedical Engineering, vol. 23, 1995, pp. 833-839.
Yang, S., et al., “Glucose Biosensors with Enzyme Entrapped in Polymer Coating”, Original Research, Biomedical Instrumentation & Technology, 1995, pp. 125-133.
U.S. Appl. No. 16/256,855, filed Nov. 22, 2022 Response to Final Office Action with Request for Continued Examination and Terminal Disclaimer.
U.S. Appl. No. 16/256,855, filed Oct. 27, 2022 Final Office Action.
U.S. Appl. No. 16/256,855, filed Oct. 12, 2022 Response to Non-Final Office Action.
Abel, et al., “Biosensors for in vivo glucose measurement: can we cross the experimental stage”, Biosensors and Bioelectronics, 17:1059-1070 (2002).
Alcock, et al., “Continuous Analyte Monitoring to Aid Clinical Practice”, IEEE Engineering in Medicine and Biology, pp. 319-325 (1994).
Bequette, “Continuous Glucose Monitoring: Real Time Algorithms for Calibration, Filtering, and Alarms”, Journal of Diabetes Science and Technology, 4(2):404-418 (2010).
Cengiz, et al., “A Tale of Two Compartments: Interstitial Versus Blood Glucose Monitoring”, Diabetes Technology & Therapeutics, 11(1):S-11-S16 (2009).
Chen, et al., “Defining the Period of Recovery of the Glucose Concentration after Its Local Perturbation by the Implantation of a Miniature Sensor”, Clin Chem Lab Med, 40(8):786-789 (2002).
De Block, et al., “Minimally-Invasive and Non-Invasive Continuous Glucose Monitoring Systems: Indications, Advantages, Limitations and Clinical Aspects”, Current Diabetes Reviews, 4:159-168 (2008).
Facchinetti, et al., “Enhanced Accuracy of Continuous Glucose Monitoring by Online Extended Kalman Filtering”, Diabetes Technology & Therapeutics, 12(5):353-363 (2010).
Gerritsen, et al., “Subcutaneously implantable glucose sensors in patients with diabetes mellitus; still many problems”, Dutch Journal of Medicine, 146(28):1313-1316 (2002) (with English Machine Translation).
Heinemann, “Continuous Glucose Monitoring by Means of the Microdialysis Technique: Underlying Fundamental Aspects”, Diabetes Technology & Therapeutics, 5(4):545-561 (2003).
Knobbe, et al., “The Extended Kalman Filter for Continuous Glucose Monitoring”, Diabetes Technology & Therapeutics, 7(1):15-27 (2005).
Koudelka, et al., “In-vivo Behaviour of Hypodermically Implanted Microfabricated Glucose Sensors”, Biosensors & Bioelectronics, 6:31-36 (1991).
Koudelka-Hep, “Electrochemical Sensors for in vivo Glucose Sensing”, Biosensors in the Body: Continuous in vivo Monitoring, pp. 57-77 (1997).
Kvist, et al., “Recent Advances in Continuous Glucose Monitoring: Biocompatibility of Glucose Sensors for Implantation in Subcutis”, Journal of Diabetes Science and Technology, 1(5):746-752 (2007).
Ming Li, et al., “Implantable Electrochemical Sensors for Biomedical and Clinical Applications: Progress, Problems, and Future Possibilities”, Current Medicinal Chemistry, 14:937-951 (2007).
Onuki, et al., “A Review of the Biocompatibility of Implantable Devices: Current Challenges to Overcome Foreign Body Response”, Journal of Diabetes Science and Technology, 2(6):1003-1015 (2008).
Palerm, et al., “Hypoglycemia Prediction and Detection Using Optimal Estimation”, Diabetes Technology & Therapeutics, 7(1):3-14 (2005).
Poitout, et al., “Calibration in dogs of a subcutaneous miniaturized glucose sensor using a glucose meter for blood glucose determination”, Biosensors & Bioelectronics, 7:587-592 (1992).
Rebrin, et al., “Subcutaneous glucose predicts plasma glucose independent of insulin: implications for continuous monitoring”, American Journal of Physiology-Endocrinology and Metabolism, 277(3):E561-E571 (1999).
Renard, “Implantable glucose sensors for diabetes monitoring”, Min Invas Ther & Allied Technol, 13(2):78-86 (2004).
Robert, “Continuous Monitoring of Blood Glucose”, Horm Res 57(suppl 1):81-84 (2002).
Schlosser, et al., “Biocompatibility of Active Implantable Devices”, Biosensors in the Body: Continuous in vivo Monitoring, pp. 139-170 (1997).
Schmidt, et al., “Calibration of a wearable glucose sensor”, The International Journal of Artificial Organs, 15(1):55-61 (1992).
Voskerician, et al., “Sensor Biocompatibility and Biofouling in Real-Time Monitoring”, Wiley Encyclopedia of Biomedical Engineering, (John Wiley & Sons, Inc.), pp. 1-19 (2006).
Ward, “A Review of the Foreign-body Response to Subcutaneously-implanted Devices: The Role of Macrophages and Cytokines in Biofouling and Fibrosis”, Journal of Diabetes Science and Technology, 2(5):768-777 (2008).
Ward, et al., “A new amperometric glucose microsensor: in vitro and short-term in vivo evaluation”, Biosensors & Bioelectronics, 17:181-189 (2002).
U.S. Appl. No. 16/256,855 (US 2019-0150802 A1), filed Jan. 24, 2019 (May 23, 2019).
U.S. Appl. No. 15/789,949 (U.S. Pat. No. 10,188,334), filed Oct. 20, 2017 (Jan. 29, 2019).
U.S. Appl. No. 15/616,916 (U.S. Pat. No. 9,801,577), filed Jun. 7, 2017 (Oct. 31, 2017).
U.S. Appl. No. 14/066,650 (U.S. Pat. No. 9,675,290), filed Oct. 29, 2013 (Jun. 13, 2017).
U.S. Appl. No. 16/256,855, Jul. 12, 2022 Non-Final Office Action.
U.S. Appl. No. 16/256,855, Jun. 23, 2022 TrackOne Request Granted.
U.S. Appl. No. 16/256,855, Jun. 1, 2022 Response to Final Office Action with Request for Continued Examination (RCE) & TrackOne Request.
U.S. Appl. No. 16/256,855, Apr. 1, 2022 Final Office Action.
U.S. Appl. No. 16/256,855, Mar. 7, 2022 Response to Non-Final Office Action.
U.S. Appl. No. 16/256,855, Jan. 7, 2022 Non-Final Office Action.
U.S. Appl. No. 16/256,855, Nov. 22, 2021 Response to Non-Final Office Action.
U.S. Appl. No. 16/256,855, Aug. 25, 2021 Non-Final Office Action.
Armour, J. C., et al., “Application of Chronic Intravascular Blood Glucose Sensor in Dogs”, Diabetes, vol. 39, 1990, pp. 1519-1526.
Arnold, M. A., et al., “Selectivity Assessment of Noninvasive Glucose Measurements Based on Analysis of Multivariate Calibration Vectors”, Journal of Diabetes Science and Technology, vol. 1, No. 4, 2007, pp. 454-462.
Bennion, N., et al., “Alternate Site Glucose Testing: A Crossover Design”, Diabetes Technology & Therapeutics, vol. 4, No. 1, 2002, pp. 25-33.
Blank, T. B., et al., “Clinical Results From a Non-Invasive Blood Glucose Monitor”, Optical Diagnostics and Sensing of Biological Fluids and Glucose and Cholesterol Monitoring II, Proceedings of SPIE, vol. 4624, 2002, pp. 1-10.
Boyne, M. S., et al., “Timing of Changes in Interstitial and Venous Blood Glucose Measured With a Continuous Subcutaneous Glucose Sensor”, Diabetes, vol. 52, Nov. 2003, pp. 2790-2794.
Bremer, T. M., et al., “Benchmark Data from the Literature for Evaluation of New Glucose Sensing Technologies”, Diabetes Technology & Therapeutics vol. 3 No. 3, 2001, pp. 409-418.
Brooks, S. L., et al., “Development of an On-Line Glucose Sensor for Fermentation Monitoring”, Biosensors, vol. 3, 1987/88, pp. 45-56.
Cass, A. E., et al., “Ferrocene-Medicated Enzyme Electrode for Amperometric Determination of Glucose”, Analytical Chemistry, vol. 56, No. 4, 1984, 667-671.
Cheyne, E. H., et al., Performance of a Continuous Glucose Monitoring System During Controlled Hypoglycaemia in Healthy Volunteers, Diabetes Technology & Therapeutics, vol. 4, No. 5, 2002, pp. 607-613.
Choleau, C., et al., “Calibration of a Subcutaneous Amperometric Glucose Sensor Implanted for 7 Days in Diabetic Patients Part 2. Superiority of the One-Point Calibration Method”, Biosensors and Bioelectronics, vol. 17, No. 8, 2002, pp. 647-654.
Csoregi, E., et al., “Design and Optimization of a Selective Subcutaneously Implantable Glucose Electrode Based on ‘Wired’ Glucose Oxidase”, Analytical Chemistry, vol. 67, No. 7, 1995, pp. 1240-1244.
Diabetes Control and Complications Trial Research Group, “The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus,” New England J. Med. vol. 329, 1993, pp. 977-986.
Eren-Oruklu, M., et al., “Estimation of Future Glucose Concentrations with Subject-Specific Recursive Linear Models”, Diabetes Technology & Therapeutics vol. 11(4), 2009, pp. 243-253.
Feldman, B., et al., “A Continuous Glucose Sensor Based on Wired Enzyme™ Technology Results from a 3-Day Trial in Patients with Type 1 Diabetes”, Diabetes Technology & Therapeutics, vol. 5, No. 5, 2003, pp. 769-779.
Feldman, B., et al., “Correlation of Glucose Concentrations in Interstitial Fluid and Venous Blood During Periods of Rapid Glucose Change”, Abbott Diabetes Care, Inc. Freestyle Navigator Continuous Glucose Monitor Pamphlet, 2004.
Georgescu, B., et al., “Real-Time Multimodel Tracking of Myocardium in Echocardiography Using Robust Information Fusion”, Medical Image Computing and Computer-Assisted Intervention, 2004, pp. 777-785.
Goldman, J. M., et al., “Masimo Signal Extraction Pulse Oximetry”, Journal of Clinical Monitoring and Computing, vol. 16, No. 7, 2000, pp. 475-483.
Guerci, B., et al., “Clinical Performance of CGMS in Type 1 Diabetic Patients Treated by Continuous Subcutaneous Insulin Infusion Using Insulin Analogs”, Diabetes Care, vol. 26, 2003, pp. 582-589.
Hovorka, R., et al., “Nonlinear Model Predictive Control of Glucose Concentration in Subjects with Type 1 Diabetes”, Physiological Measurement, vol. 55, Jul. 2004, pp. 905-920.
Isermann, R., “Supervision, Fault-Detection and Fault-Diagnosis Methods—an Introduction”, Control Engineering Practice, vol. 5, No. 5, 1997, pp. 639-652.
Isermann, R., et al., “Trends in the Application of Model-Based Fault Detection and Diagnosis of Technical Processes”, Control Engineering Practice, vol. 5, No. 5, 1997, pp. 709-719.
Johnson, P. C., “Peripheral Circulation”, John Wiley & Sons, 1978, pp. 198.
Jungheim, K., et al., “How Rapid Does Glucose Concentration Change in Daily Life of Patients with Type 1 Diabetes?”, 2002, pp. 250.
Jungheim, K., et al., “Risky Delay of Hypoglycemia Detection by Glucose Monitoring at the Arm”, Diabetes Care, vol. 24, No. 7, 2001, pp. 1303-1304.
Kaplan, S. M., “Wiley Electrical and Electronics Engineering Dictionary”, IEEE Press, 2004, pp. 141, 142, 548, 549.
Kovatchev, B. P., et al., “Evaluating the Accuracy of Continuous Glucose-Monitoring Sensors”, Diabetes Care, vol. 27, No. 8, 2004, pp. 1922-1928.
Kovatchev, B. P., et al., “Graphical and Numerical Evaluation of Continuous Glucose Sensing Time Lag”, Diabetes Technology & Therapeutics, vol. 11, No. 3, Feb. 2009, pp. 139-143.
Kuure-Kinsey, M., et al., “A Dual-Rate Kalman Filter for Continuous Glucose Monitoring”, Proceedings of the 28th IEEE, EMBS Annual International Conference, New York City, 2006, pp. 63-66.
Lodwig, V., et al., “Continuous Glucose Monitoring with Glucose Sensors: Calibration and Assessment Criteria”, Diabetes Technology & Therapeutics vol. 5 No. 4 2003, pp. 573-587.
Lortz, J., et al., “What is Bluetooth? We Explain the Newest Short-Range Connectivity Technology”, Smart Computing Learning Series, Wireless Computing, vol. 8, Issue 5, 2002, pp. 72-74.
Maher, “A Method for Extrapolation of Missing Digital Audio Data”, Preprints of Papers Presented at the AES Convention, 1993, pp. 1-19.
Maher, “Audio Enhancement using Nonlinear Time-Frequency Filtering”, AES 26th International Conference, 2005, pp. 1-9.
Malin, S. F., et al., “Noninvasive Prediction of Glucose by Near-Infrared Diffuse Reflectance Spectoscopy”, Clinical Chemistry, vol. 45, No. 9, 1999, pp. 1651-1658.
McGarraugh, G., et al., “Glucose Measurements Using Blood Extracted from the Forearm and the Finger”, TheraSense, Inc., 2001, 16 Pages.
McGarraugh, G., et al., “Physiological Influences on Off-Finger Glucose Testing”, Diabetes Technology & Therapeutics, vol. 3, No. 3, 2001, pp. 367-376.
McKean, B. D., et al., “A Telemetry-Instrumentation System for Chronically Implanted Glucose and Oxygen Sensors”, IEEE Transactions on Biomedical Engineering, vol. 35, No. 7, 1988, pp. 526-532.
Morbiducci, U, et al., “Improved Usability of the Minimal Model of Insulin Sensitivity Based on an Automated Approach and Genetic Algorithms for Parameter Estimation”, Clinical Science, vol. 112, 2007, pp. 257-263.
Mougiakakou, et al., “A Real Time Simulation Model of Glucose-Insulin Metabolism for Type 1 Diabetes Patients”, Proceedings of the 2005 IEEE, 2005, pp. 298-301.
Panteleon, A. E., et al., “The Role of the Independent Variable to Glucose Sensor Calibration”, Diabetes Technology & Therapeutics, vol. 5. No. 3, 2003, pp. 401-410.
Parker, R., et al., “Robust H..° Glucose Control in Diabetes Using a Physiological Model”, AIChE Journal, vol. 46, No. 12, 2000, pp. 2537-2549.
Pickup, J., et al., “Implantable Glucose Sensors: Choosing the Appropriate Sensing Strategy”, Biosensors, vol. 3, 1987/88, pp. 335-346.
Pickup, J., et al., “In Vivo Molecular Sensing in Diabetes Mellitus: An Implantable Glucose Sensor with Direct Electron Transfer”, Diabetologia, vol. 32, 1989, pp. 213-217.
Pishko, M. V., et al., “Amperometric Glucose Microelectrodes Prepared Through Immobilization of Glucose Oxidase in Redox Hydrogels”, Analytical Chemistry, vol. 63, No. 20, 1991, pp. 2268-2272.
Quinn, C. P., et al., “Kinetics of Glucose Delivery to Subcutaneous Tissue in Rats Measured with 0.3-mm Amperometric Microsensors”, The American Physiological Society, 1995, E155-E161.
Rodriguez, N., et al., “Flexible Communication and Control Protocol for Injectable Neuromuscular Interfaces”, IEEE Transactions on Biomedical Circuits and Systems, vol. 1, No. 1, 2007. pp. 19-27.
Roe, J. N., et al., “Bloodless Glucose Measurements”, Critical Review in Therapeutic Drug Carrier Systems, vol. 15, Issue 3, 1998, pp. 199-241.
Sakakida, M., et al., “Development of Ferrocene-Mediated Needle-Type Glucose Sensor as a Measure of True Subcutaneous Tissue Glucose Concentrations”, Artificial Organs Today, vol. 2, No. 2, 1992, pp. 145-158.
Sakakida, M., et al., “Ferrocene-Mediated Needle-Type Glucose Sensor Covered with Newly Designed Biocompatible Membrane”, Sensors and Actuators B, vol. 13-14, 1993, pp. 319-322.
Salehi, C., et al., “A Telemetry-Instrumentation System for Long-Term Implantable Glucose and Oxygen Sensors”, Analytical Letters, vol. 29, No. 13, 1996, pp. 2289-2308.
Schmidtke, D. W., et al., “Measurement and Modeling of the Transient Difference Between Blood and Subcutaneous Glucose Concentrations in the Rat After Injection of Insulin”, Proceedings of the National Academy of Sciences, vol. 95, 1998, pp. 294-299.
Shaw, G. W., et al., “In Vitro Testing of a Simply Constructed, Highly Stable Glucose Sensor Suitable for Implantation in Diabetic Patients”, Biosensors & Bioelectronics, vol. 6, 1991, pp. 401-406.
Shichiri, M., et al., “Glycaemic Control in Pancreatectomized Dogs with a Wearable Artificial Endocrine Pancreas”, Diabetologia, vol. 24, 1983, pp. 179-184.
Shichiri, M., et al., “In Vivo Characteristics of Needle-Type Glucose Sensor—Measurements of Subcutaneous Glucose Concentrations in Human Volunteers”, Hormone and Metabolic Research Supplement Series, vol. 20, 1988, pp. 17-20.
Shichiri, M., et al., “Membrane Design for Extending the Long-Life of an Implantable Glucose Sensor”, Diabetes Nutrition and Metabolism, vol. 2, 1989, pp. 309-313.
Shichiri, M., et al., “Needle-type Glucose Sensor for Wearable Artificial Endocrine Pancreas”, Implantable Sensors for Closed-Loop Prosthetic Systems, Chapter 15, 1985, pp. 197-210.
Shichiri, M., et al., “Telemetry Glucose Monitoring Device With Needle-Type Glucose Sensor: A Useful Tool for Blood Glucose Monitoring in Diabetic Individuals”, Diabetes Care, vol. 9, No. 3, 1986, pp. 298-301.
Shichiri, M., et al., “Wearable Artificial Endocrine Pancreas With Needle-Type Glucose Sensor”, The Lancet, 1982, pp. 1129-1131.
Shults, M. C., et al., “A Telemetry-Instrumentation System for Monitoring Multiple Subcutaneously Implanted Glucose Sensors”, IEEE Transactions on Biomedical Engineering, vol. 41, No. 10, 1994, pp. 937-942.
Steil, G. M., et al., “Closed-Loop Insulin Delivery—the Path of Physiological Glucose Control”, Advanced Drug Delivery Reviews, vol. 56, 2004, pp. 125-144.
Steil, G. M., et al., “Determination of Plasma Glucose During Rapid Glucose Excursions with a Subcutaneous Glucose Sensor”, Diabetes Technology & Therapeutics, vol. 5, No. 1, 2003, pp. 27-31.
Sternberg, R., et al., “Study and Development of Multilayer Needle-Type Enzyme-Based Glucose Microsensors”, Biosensors, vol. 4, 1988, pp. 27-40.
Thompson, M., et al., “In Vivo Probes: Problems and Perspectives”, Clinical Biochemistry, vol. 19, 1986, pp. 255-261.
Turner, A., et al., “Diabetes Mellitus: Biosensors for Research and Management”, Biosensors, vol. 1, 1985, pp. 85-115.
Updike, S. J., et al., “Principles of Long-Term Fully Implanted Sensors with Emphasis on Radiotelemetric Monitoring of Blood Glucose from Inside a Subcutaneous Foreign Body Capsule (FBC)”, Biosensors in the Body: Continuous in vivo Monitoring, Chapter 4, 1997, pp. 117-137.
Velho, G., et al., “Strategies for Calibrating a Subcutaneous Glucose Sensor”, Biomedica Biochimica Acta, vol. 48, 1989, pp. 957-964.
Whipple, G., “Low Residual Noise Speech Enhancement Utilizing Time-Frequency”, Proceedings of the International Conference on Acoustics, Speech, and Signal Processing, vol. 19, 1994, pp. I5-I8.
Wilson, G. S., et al., “Progress Toward the Development of an Implantable Sensor for Glucose”, Clinical Chemistry, vol. 38, No. 9, 1992, pp. 1613-1617.
Wolfe, P. J., et al., “Interpolation of Missing Data Values for Audio Signal Restoration Using a Gabor Regression Model”, 2005 IEEE International Conference on Acoustics, Speech, and Signal Processing, vol. 5, 2005, pp. 517-520.
European Patent Application No. 13275272.6, Extended European Search Report dated Mar. 3, 2014.
U.S. Appl. No. 14/066,650, Notice of Allowance dated Feb. 16, 2017.
U.S. Appl. No. 14/066,650, Office Action dated Sep. 23, 2016.
U.S. Appl. No. 14/077,004, Office Action dated Jul. 26, 2016.
U.S. Appl. No. 15/616,916, Notice of Allowance dated Sep. 7, 2017.
U.S. Appl. No. 15/789,949, Notice of Allowance dated Dec. 18, 2018.
U.S. Appl. No. 15/789,949, Office Action dated Dec. 4, 2018.
U.S. Appl. No. 15/789,949, Office Action dated May 3, 2018.
U.S. Appl. No. 15/796,274, Notice of Allowance dated Jul. 20, 2018.
U.S. Appl. No. 15/334,274, Office Action dated Apr. 25, 2019.
Chen, et al., “A novel fault-tolerant sensor system for sensor drift compensation”, Sensors and Actuators, A 147:623-632 (2008).
Gerritsen, et al., “Performance of subcutaneously implanted glucose sensors for continuous monitoring”, The Netherlands Journal of Medicine, 54:167-179 (1999).
Kalivas, et al., “Compensation for Drift and Interferences in Multicomponent Analysis”, Laboratory for Chemometrics, Department of Chemistry, University of Washington, 38 pages (1982).
Thévenot, et al., “Electrochemical Biosensors: Recommended Definitions and Classification (Technical Report)”, Pure Appl. Chem. 71(12):2333-2348 (1999).
U.S. Appl. No. 12/842,013 Office Action mailed Aug. 26, 2015.
U.S. Appl. No. 12/842,013 Office Action mailed Mar. 23, 2016.
U.S. Appl. No. 12/842,013 Office Action mailed Nov. 6, 2014.
Walt, et al., “The chemistry of enzyme and protein immobilization with glutaraldehyde”, Trends in Analytical Chemistry, 13(10):425-430 (1994).
Zhang, “Investigations of potentially implantable glucose sensors”, University of Kansas, 24 pages (1991).
U.S. Appl. No. 60/687,199, filed Jun. 2, 2005, Ward, et al.
U.S. Appl. No. 61/155,889, filed Feb. 26, 2009, Hoss, et al.
U.S. Appl. No. 18/173,901, May 25, 2023, Non-Final Office Action.
Atanasov, et al., “Implantation of a refillable glucose monitoring-telemetry device”, Biosensors & Bioelectronics, 12(7):669-680 (1997).
Bindra, “Development of potentially implantable glucose sensors”, The University of Arizona, 227 pages (1990).
Choleau, et al., “Calibration of a subcutaneous amperometric glucose sensor Part 1. Effect of measurement uncertainties on the determination of sensor sensitivity and background current”, Biosensors and Bioelectronics, 17:641-646 (2002).
Guardian® Real-Time, Continuous Glucose Monitoring System, User Guide, Medtronic MiniMed, Inc., 184 pages (2006).
Kerner, et al., The function of a hydrogen peroxide-detecting electroenzymatic glucose electrode is markedly impaired in human sub-cutaneous tissue and plasma, Biosensors & Bioelectronics, 8:473-482 (1993).
Koschinsky, et al., “Sensors for glucose monitoring: technical and clinical aspects”, Diabetes/Metabolism Research and Reviews, 17:113-123 (2001).
Koschwanez, et al., “In vitro, in vivo and post explantation testing of glucose-detecting biosensors: Current methods and recommendations”, Biomaterials, 28:3687-3703 (2007).
Moussy, et al. “Performance of Subcutaneously Implanted Needle-Type Glucose Sensors Employing a Novel Trilayer Coating”, Anal. Chem., 65:2072-2077 (1993).
Pickup, et al., “In vivo glucose sensing for diabetes management: progress towards non-invasive monitoring”, BMJ, 319, pp. 1-4 (1999).
Pickup, et al., “Responses and calibration of amperometric glucose sensors implanted in the subcutaneous tissue of man”, Acta Diabetol, 30:143-148 (1993).
Schmidtke, et al., “Accuracy of the One-Point in Vivo Calibration of “Wired” Glucose Oxidase Electrodes Implanted in Jugular Veins of Rats in Periods of Rapid Rise and Decline of the Glucose Concentration”, Anal. Chem., 70:2149-2155 (1998).
Ward, et al., “Rise in background current over time in a subcutaneous glucose sensor in the rabbit: relevance to calibration and accuracy”, Biosensors & Bioelectronics, 15:53-61 (2000).
Wilson, et al., “Biosensors for real-time in vivo measurements”, Biosensors and Bioelectronics, 20:2388-2403 (2005).
Wisniewski, et al., “Analyte flux through chronically implanted subcutaneous polyamide membranes differs in humans and rats”, Am J Physiol Endocrinol Metab, 282:E1316-E1323 (2002).
Abbott receives CE Mark for Freestyle® Libre, a revolutionary glucose monitoring system for people with diabetes, 8 pages (2023).
An Interview with Kevin Sayer, President and CEO of Dexcom, About The New Dexcom G6, 6 pages (2021).
Cambridge Dictionary of American English, for the word “recess,” Cambridge University Press, 3 pages (2000).
Certified Preliminary Amendment for U.S. Pat. No. 10,827,954, issued on Nov. 10, 2020.
Certified Preliminary Amendment for U.S. Pat. No. 10,973,443, issued on Apr. 13, 2021.
CGMS Changing Diabetes Management: Kevin Sayer, DIC Interview Transcript, 11 pages (2019).
Deciding When to Submit a 510(k) for a Change to an Existing Device, Guidance for Industry and Food and Drug Administration Staff, U.S. Department of Health and Human Services, Food and Drug Administration, 78 pages (2017).
Deciding When to Submit a 510(k) for a Software Change to an Existing Device, Guidance for Industry and Food and Drug Administration Staff, U.S. Department of Health and Human Services, Food and Drug Administration, 32 pages (2017).
Dexcom (DXCM) / Feb. 27, 2018 / 2017 Q4 Earnings call transcript, 12 pages (2017).
DexCom (DXCM) Q1 2018 Results—Earnings Call Transcript, 4 pages (2018).
Dexcom CEO—Prime Position in Our Market—Mad Money—CNBC.mp4, 4 pages (2023).
Dexcom G6, Continuous Glucose Monitoring System, User Guide, 22 pages (2020).
Dexcom G6, Continuous Glucose Monitoring System, User Guide, 7 pages (2020).
Dexcom G6, Start Here Set Up, Dexcom G6 Continuous Glucose Monitoring (CGM) System (G6), 8 pages (2019).
Dexcom G6, Using Your G6, 7 pages (2020).
DexCom, Inc. NasdaqGS:DXCM, Company Conference Presentation, 10 pages (2020).
DexCom, Inc. NasdaqGS:DXCM, Company Conference Presentation, 11 pages (2019).
DexCom, Inc. NasdaqGS:DXCM, Company Conference Presentation, 17 pages (2021).
Email from Sophie Hood to Matthew Werdegar and Manuela Cabal re. Abbott Diabetes Care, Inc et al. v. DexCom, Inc. | Case No. 21-977-KAJ, dated Jan. 24, 2023.
FDA News Release, FDA authorizes first fully interoperable continuous glucose monitoring system, streamlines review pathway for similar devices, 3 pages (2018).
Figures 13 and 12 of U.S. Pat. No. 10,973,443 B2 issued on Apr. 13, 2021.
Hoss, et al., Continuous Glucose Monitoring in Subcutaneous Tissue Using Factory-Calibrated Sensors: A Pilot Study, Diabetes Technology & Therapeutics, vol. 12, No. 8, pp. 591-597 (2010).
Hoss, et al., Continuous glucose monitoring in the tissue: Do we really need to calibrate in-Vivo?, Abbott Diabetes Care, 23 pages (2009).
Hoss, et al., Feasibility of Factory Calibration for Subcutaneous Glucose Sensors in Subjects with Diabetes, Journal of Diabetes Science and Technology, vol. 8(1), pp. 89-94 (2014).
IEEE 100, The Authoritative Dictionary, Seventh Edition, Standards Information Network, IEEE Press, 3 pages (2000).
Interview with Dexcom CEO, Dexcom CEO Kevin Sayer Explains G6, Written by: Michelle Boise, 10 pages—Exhibit 113 (2018).
Interview with Dexcom CEO, Dexcom CEO Kevin Sayer Explains G6, Written by: Michelle Boise, 10 pages—Exhibit 158 (2018).
Interview with Dexcom CEO, Dexcom CEO Kevin Sayer Explains G6, Written by: Michelle Boise, 9 pages (2018).
Joint Declaration under 37 C.F.R. § 1.131 for U.S. Appl. No. 15/963,828 (2020).
Letter from Department of Health & Human Services to Abbott Diabetes Care, Inc. re. PMA approval for P050020, FreeStyle Navigator Continuous Glucose Monitoring System, dated Mar. 12, 2008.
Merriam-Webster's Collegiate Dictionary, Tenth Edition for the words “housing” and “recess,” Merriam-Webster, Incorporated, 4 pages (1999).
Merriam-Webster's Collegiate Dictionary, Tenth Edition for the words “release” and “retain,” Merriam-Webster, Incorporated, 4 pages (1999).
Non-Final Office Action for U.S. Appl. No. 14/884,622, mailed on Jun. 13, 2018.
Non-Final Office Action for U.S. Appl. No. 17/030,030, issued on Dec. 17, 2020.
Notice of Allowance for U.S. Appl. No. 15/963,828, mailed on Mar. 3, 2021.
Omnipod image, Exhibit 182, 2 pages (Sep. 22, 2022).
Program Book, 2nd International Conference on Advanced Technologies & Treatments for Diabetes, Athens, Greece, 4 pages (2009).
Response to Non-Final Office Action under 37 C.F.R. 1.111 for U.S. Appl. No. 15/963,828, filed Dec. 8, 2020.
Response to Restriction Requirement for U.S. Appl. No. 14/884,622, filed Apr. 5, 2018.
Spruce Point Capital Management, Dexcom, Inc., Investment Research Report, Does Dexcom Really Have A Future If It Can't Match Abbott's Scale? 2 pages (Mar. 21, 2019).
Tegnestedt, et al., Levels and sources of sound in the intensive care unit—an observational study of three room types, Acta Anaesthesiol Scandinavica Foundation, 11 pages (2013).
The Chambers Dictionary for the word “retract,” Chambers Harrap Publishers Ltd, 4 pages (1998).
The MiniMed Paradigm® Real-Time Insulin Pump and Continuous Glucose Monitoring System, Insulin Pump User Guide, Medtronic, Paradigm® 522 and 722 Insulin Pumps User Guide, 25 pages (2008).
The New Oxford American Dictionary, for the word “retract,” Oxford University Press, 3 pages (2001).
The New Penguin English Dictionary, for the word “recess,” Penguin Books, 4 pages (2000).
Watkin, An Introduction to Flash Glucose Monitoring, 16 pages (2013).
Webster's II New College Dictionary, for the word “alcove,” 2 pages (2001).
Webster's Third New International Dictionary of the English Language Unabridged, for the word “retract,” Merriam-Webster Inc., 5 pages (1993).
Hoss, U. et al., “Factory-Calibrated Continuous Glucose Sensors: The Science Behind the Technology”, Diabetes Technology & Therapeutics, vol. 19, Suppl. 2, pp. S-44-S-50 (2017).
Dock, E. et al., “Multivariate data analysis of dynamic amperometric biosensor responses from binary analyte mixtures—application of sensitivity correction algorithms”, Talanta, 65, pp. 298-305 (2005).
Hanson, K. et al., “Comparison of Point Accuracy Between Two Widely Used Continuous Glucose Monitoring Systems”, Journal of Diabetes Science and Technology, 2024, pp. 1-10.
Abbott Press Release—“Abbott Receives CE Mark for FreeStyle® Libre, A Revolutionary Glucose Monitoring System for People with Diabetes” retrieved from https://abbott.mediaroom.com/2014-09-03-Abbott-Receives-CE-Mark-for-FreeStyle-Libre-a-Revolutionary-Glucose-Monitoring-System-for-People-with-Diabetes/, Sep. 3, 2014, 3 pages.
Abbott Press Release—“Abbott Receives FDA Approval for the FreeStyle Libre Pro™ System, A Revolutionary Diabetes Sensing Technology for Healthcare Professionals to Use with their Patients” retrieved from https://abbott.mediaroom.com/2016-09-28-Abbott-Receives-FDA-Approval-for-the-FreeStyle-Libre-Pro-System-a-Revolutionary-Diabetes-Sensing-Technology-for-Healthcare-Professionals-to-use-with-their-Patients/, Sep. 28, 2016, 5 pages.
Abbott Press Release—“Abbott's FreeStyle® Libre 14 Day Flash Glucose Monitoring System Now Approved in U.S.” retrieved from https://abbott.mediaroom.com/2018-07-27-Abbotts-FreeStyle-R-Libre-14-Day-Flash-Glucose-Monitoring-System-Now-Approved-in-U-S/, Jul. 27, 2018, 3 pages.
Alcock, et al., “Continuous Analyte Monitoring to Aid Clinical Practice”, IEEE Engineering in Medicine and Biology, vol. 13, No. 3, pp. 319-325 (1994).
ANZHSN, National Horizon Scanning Unit Horizon Scanning Report, “GlucoWatch® G2 Biographer for the non-invasive monitoring of glucose levels”, 46 pages, May 2004.
Cather, CGM Frustrations Survey dated Jun. 2020, 37 pages in Abbott Diabetes Care Inc., et al. v. Dexcom, Inc., Case No. 1:21-cv-00977-KAJ (District of Delaware).
Chen, et al., “In vivo Glucose Monitoring with Miniature “Wired” Glucose Oxidase Electrodes”, Analytical Sciences, vol. 17 Supplement, pp. i297-i300 (2001).
Clinical Trials, Competitor and Ecosystem Players dated Jun. 25, 2020, 29 pages in Abbott Diabetes Care Inc., et al. v. Dexcom, Inc., Case No. 1:21-cv-00977-KAJ (District of Delaware).
Declaration of Dr. Anthony Edward Cass in Support of Petition for Inter Partes Review of U.S. Pat. No. 11,020,031 in Abbott Diabetes Care Inc. v. Dexcom, Inc., Case No. IPR2024-00890, In the United States Patent and Trademark Office, Before the Patent Trial and Appeal Board, May 10, 2024, 138 pages.
Declaratiom of Karl R. Leinsing, MSME, PE, in Support of Abbott's Motion for Summary Judgment dated May 19, 2023, 81 pages in Abbott Diabetes Care Inc., et al. v. Dexcom Inc., Case No. 1:21-CV-00977-KAJ (District of Delaware).
Dock, et al., “Multivariate data analysis of dynamic amperometric biosensor responses from binary analyte mixtures—application of sensitivity correction algorithms”, Talanta, 65:298-305 (2005).
Effectiveness and Safety Study of the DexCom™ G4 Continuous Glucose Monitoring System, DexCom, Inc, U.S. National Library of Medicine, ClinicalTrials.gov Identifier: NCT01111370, 4 pages (2017).
E-mail Communication from Christopher M. Dougherty regarding Bi Monthly Global Commercial Insights Meeting dated Dec. 17, 2019, 69 pages in Abbott Diabetes Care Inc., et al. v. Dexcom, Inc., Case No. 1:21-cv-00977-KAJ (District of Delaware).
Feldman, et al., “A Continuous Glucose Sensor Based on Wired Enzyme™ Technology—Results from a 3-Day Trial in Patients with Type 1 Diabetes”, Diabetes Technology & Therapeutics, vol. 5, No. 5, pp. 769-779 (2003).
Design U.S. Appl. No. 29/101,218, filed Feb. 25, 1999, 11 pages.
U.S. Pat. No. 11,020,031 issued Jun. 1, 2021, 1058 pages.
Fraser, “An Introduction to in vivo Biosensing: Progress and Problems”, Biosensors in the Body: Continuous In Vivo Monitoring, pp. 1-56 (1997).
FreeStyle Libre 2 HCP Pulse, Mar. 2021 Report, dated Mar. 1, 2021, 14 pages in Abbott Diabetes Care Inc., et al. v. Dexcom, Inc., Case No. 1:21-CV-00977-KAJ (District of Delaware).
FreeStyle Navigator Continuous Glucose Monitoring System, User's Guide, Abbott Diabetes Care Inc., 38 pages (2008).
Frost, et al., “Implantable chemical sensors for real-time clinical monitoring: progress and challenges”, Current Opinion in Chemical Biology, 6:633-641 (2002).
Godek, et al., Chapter 2, “The Macrophage in Wound Healing Surrounding Implanted Devices”, In Vivo Glucose Sensing, 36 pages (2010).
Gross, et al., “Performance Evaluation of the MiniMed® Continuous Glucose Monitoring System During Patient Home Use”, Diabetes Technology & Therapeutics, vol. 2, No. 1, pp. 49-56 (2000).
Heller, “Implanted Electrochemical Glucose Sensors for the Management of Diabetes”, Annu. Rev. Biomed. Eng., 01:153-175 (1999).
Heller, “Integrated Medical Feedback Systems for Drug Delivery”, American Institute of Chemical Engineers Journal, vol. 51, No. 4, pp. 1054-1066 (2005).
Heller, et al., “Electrochemical Glucose Sensors and Their Applications in Diabetes Management”, Chem. Rev., 108, Parts 1-3, pp. 2482-2505 (2008).
Henning, Chapter 5, “Commercially Available Continuous Glucose Monitoring Systems”, In Vivo Glucose Sensing, 50 pages (2010).
Koudelka-Hep, “Electrochemical Sensors for in vivo Glucose Sensing”, Biosensors in the Body: Continuous In Vivo Monitoring, 12 pages (1997).
Kovatchev, et al., “Evaluating the Accuracy of Continuous Glucose-Monitoring Sensors”, Diabetes Care, vol. 27, No. 8, pp. 1922-1928 (2004).
Lesperance, et al., “Calibration of the Continuous Glucose Monitoring System for Transient Glucose Monitoring”, Diabetes Technology & Therapeutics, vol. 9, No. 2, pp. 183-190 (2007).
Nishida, et al., “Development of a ferrocene-mediated needle-type glucose sensor covered with newly designed biocompatible membrane, 2-methacryloyloxyethyl phosphorylcholine-co-n-butyl methacrylate”, Medical Progress through Technology, 21:91-103 (1995).
Project Status Update, Glucose Sensor Applicator Dexcom (project #2554), Design Concepts, Inc., 6 pages (2014).
Schlosser, et al., “Biocompatibility of Active Implantable Devices”, Biosensors in the Body: Continuous in vivo Monitoring, 34 pages (1997).
Schmidt, et al., “Calibration of a wearable glucose sensor”, The International Journal of Artificial Organs, vol. 15, No. 1, pp. 55-61 (1992).
Seagrove Partners, International Diabetes Device, 2022 Blue Book dated 2022, 143 pages in Abbott Diabetes Care Inc., et al. v. Dexcom, Inc., Case No. 1:21-cv-00977-KAJ (District of Delaware).
Velho, et al., “Strategies for calibrating a subcutaneous glucose sensor”, Biomed. Biochim. Acta 48:11/12, pp. 957-964 (1989).
Wilson et al., Chapter 1, “Introduction to the Glucose Sensing Problem,” In Vivo Glucose Sensing, 32 pages (2010).
Wisniewski, et al., “Characterization of implantable biosensor membrane biofouling”, Fresenius J Anal Chem, 366:611-621 (2000).
Dorland's Illustrated Medical 31st Edition Dictionary, definition of “fluid, intersitial”, (2007), 3 pages.
Forlenza, G.P., et al., “Factory-Calibrated Continuous Glucose Monitoring: How and Why It Works, and the Dangers of Reuse Beyond Approved Duration of Wear”, Diabetes Technology & Therapeutics, vol. 21, No. 4, (2019) 13 pages.
Stephens Inc., Research Bulletin, “DexCom, Inc., A True Game Changer: The G6 Eliminates Fingersticks”, (2018) 5 pages.
The American Hertiage® Medical Dictionary, definition of “cathether” and “interstitial fluid”, (2007), 4 pages.
Related Publications (1)
Number Date Country
20220142518 A1 May 2022 US
Provisional Applications (1)
Number Date Country
61720393 Oct 2012 US
Continuations (4)
Number Date Country
Parent 16256855 Jan 2019 US
Child 17580579 US
Parent 15789949 Oct 2017 US
Child 16256855 US
Parent 15616916 Jun 2017 US
Child 15789949 US
Parent 14066650 Oct 2013 US
Child 15616916 US